EP3046552A1 - Composition involved in regulating energy cycle, inflammation and insulin resistance dysfunctions, and use thereof particularly in cardiometabolic diseases - Google Patents

Composition involved in regulating energy cycle, inflammation and insulin resistance dysfunctions, and use thereof particularly in cardiometabolic diseases

Info

Publication number
EP3046552A1
EP3046552A1 EP14744782.5A EP14744782A EP3046552A1 EP 3046552 A1 EP3046552 A1 EP 3046552A1 EP 14744782 A EP14744782 A EP 14744782A EP 3046552 A1 EP3046552 A1 EP 3046552A1
Authority
EP
European Patent Office
Prior art keywords
composition
composition according
vitamin
ampk
excipients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14744782.5A
Other languages
German (de)
French (fr)
Inventor
Claude Vincent
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International Nutrition Research Co SRL
Original Assignee
International Nutrition Research Co SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1356450A external-priority patent/FR3007987A1/en
Priority claimed from FR1356448A external-priority patent/FR3007986A1/en
Priority claimed from FR1356444A external-priority patent/FR3007984A1/en
Priority claimed from FR1356446A external-priority patent/FR3007985A1/en
Application filed by International Nutrition Research Co SRL filed Critical International Nutrition Research Co SRL
Publication of EP3046552A1 publication Critical patent/EP3046552A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)

Definitions

  • the present invention relates to a specific composition and its use as a health product especially for the prevention of cardiometabolic risk, for the prevention and treatment of cardiometabolic diseases, and for the prevention and treatment of infertility and / or -fertility of overweight people.
  • Metabolic syndrome refers to the presence in an individual of several clinical and biological signs that indicate the onset of heart disease and type II diabetes, although these signs are not necessarily felt by the person affected. It is characterized by the association of several manifestations, in particular an important abdominal perimeter and / or a high level of triglycerides in the blood and / or an increase in glucose intolerance (high blood sugar) and / or insulin resistance and / or or decreased arterial hypertension and / or HDL and / or increased fibrinogen and / or inflammatory adipocytokines: TNFa ("Tumor Necrosis Factor a" tumor necrosis factor a), IL6 (Interleukin 6), PAI-1 (“Plasminogen activator inhibitor-1” activator inhibitor plasminogen-1), CRP (“C-reactive protein C-reactive protein) ultrasensitive, which cause a decrease in adiponectin and serotonin which are central hormones in this type of dysfunction.
  • TNFa Tumor Necrosis Factor
  • This chronic inflammation is responsible for the formation of fatty plaques in the vessels, which are deposited on the walls (angina pectoris and arteritis of the lower limbs) and eventually rupture (infarction and stroke) by the action of one of the adipocytokines of inflammation the CRPus (ultra-sensitive reactive protein C).
  • CRPus ultra-sensitive reactive protein C
  • free radicals by the formation of their waste, interfere with the exchanges at the level of the cells causing intolerance to glucose, an insulin resistance and diabetes by a matrix remodeling of the cell.
  • the liver is particularly sensitive to the metabolic syndrome since it is the first place of deposit of triglycerides and with the increase in storage occurs a fatty liver that can evolve into NAFLD (Nonalcoholic Fatty Liver Disease non-alcoholic fatty liver disease ), NASH ("nonalcoholic steatohepatitis” nonalcoholic steatohepatitis) with fibrosis more or less important and progressive to cirrhosis and cancer.
  • NAFLD Nonalcoholic Fatty Liver Disease non-alcoholic fatty liver disease
  • NASH nonalcoholic steatohepatitis
  • nonalcoholic steatohepatitis nonalcoholic steatohepatitis
  • the objective of the present invention is to propose a different solution acting on specific pathways of the metabolic syndrome, easy to use and effective, which is capable of preventing cardiometabolic risk, preventing fatty liver and treating pre-diabetes, but also to treat cardiovascular diseases in general and to prevent and treat infertility and sub-fertility in men and women.
  • the present invention proposes to act both on the adiponectin and serotonin levels and to provide amino acids and small active biopeptides, with an action at the cellular level on the cycle of the AMP (adenosine monophosphate) and ATP (adenosine triphosphate) energy through AMP-activated protein kinase (AMPK), MAPK ("mitogen-activated protein kinase"), PPAR ("peroxisome proliferator activated receptors”) and SIRT1 (sirtuin 1), and on the cycles of inflammation and insulin resistance.
  • AMPK AMP-activated protein kinase
  • MAPK mitogen-activated protein kinase
  • PPAR peroxisome proliferator activated receptors
  • SIRT1 sinuin 1
  • the invention provides a composition suitable for use as an oral health product, in particular as a medical or medicinal product, comprising a mixture of active ingredients consisting of at least:
  • whey hydrolyzate with a molecular weight of between 200 and 5,000 daltons
  • At least one regulator of the AMPK and / or MAPK and / or PPAR ⁇ and ⁇ and / or SIRT1 cycles in particular a thiazolinedione mimetic or agonist, chosen from the family of tocopherols and vitamin B6 and leucine and the family of branched amino acids, and
  • such a composition makes it possible to reduce visceral fat, liver fat and deep subcutaneous fat, in particular by allowing an increase in adiponectin and serotonin levels. It can be used as a health product, particularly in the prevention of cardiometabolic risk and / or hepatic steatosis and / or in the prevention and / or treatment of pre-diabetes (avoiding the transition from pre-diabetes to type II diabetes), diabetes type II, cardiovascular disease and / or infertility and / or subfertility in overweight men or women. It is involved in the regulation of the dysfunction of energy cycles, inflammation and insulin resistance.
  • it is used in addition to a life-style change involving, in particular, a particular diet, a caloric restriction, the practice of a physical activity, the management of chronic stress and the management of an anxiety state requiring a therapeutic education of the patient. patient.
  • the invention therefore relates to a composition adapted for use as an oral health product, comprising a mixture of active ingredients consisting of at least:
  • whey hydrolyzate with a molecular weight of between 200 and 5,000 daltons
  • At least one regulator of the AMPK and / or MAPK and / or PPAR ⁇ and ⁇ and / or SIRT1 cycles chosen from the tocopherol family, vitamin B6, leucine and the branched amino acid family, and
  • the composition may also contain at least one active pharmaceutical ingredient that regulates AMPK and / or MAPK cycles and / or PPARs ⁇ and ⁇ and / or
  • SIRT1 selected from metformin and statins.
  • health product within the meaning of the invention is meant any product acting in favor of human health, including a drug or a medical nutrition product.
  • medical nutrition product within the meaning of the invention is meant a therapeutic food for prevention or treatment, used alone or in combination with other therapies.
  • composition according to the invention is particularly suitable for persons wishing to lose visceral fat, hepatic fat and / or subcutaneous fat, in particular for medical reasons of primary or secondary or tertiary prevention of diseases.
  • pre diabetes pre-type II diabetes and these terms are used interchangeably to describe the present invention.
  • diabetes is defined as type II diabetes and these terms are used interchangeably to describe the present invention.
  • Cardiometabolic risk is defined as a syndrome that includes at least 3 risk factors such as waist circumference, blood glucose and blood pressure, HDL cholesterol, smoking and heredity.
  • This metabolic syndrome leads to several pathologies that are in particular: type II diabetes, atherosclerosis, ischemic coronary artery disease, cerebrovascular dementia, stroke, arterial occlusive disease of the lower limbs, metabolic infertility, liver diseases: steatosis, fibrosis, cirrhosis.
  • Whey hydrolyzate within the meaning of the invention is understood to mean any molecule or mixture of molecules obtained from whey, in particular whey hydrolysed by a process comprising a chemical hydrolysis or enzymatic hydrolysis step.
  • whey hydrolyzate In a particularly suitable way, it is a peptide hydrolyzate. It preferably comprises at least 75% of proteins or peptides, by weight of the hydrolyzate.
  • the whey hydrolyzate has a molecular weight of between 200 and 5000 daltons. Preferably at least 55% of the total molecules of the whey hydrolyzate has a molecular weight less than or equal to 1000 daltons.
  • the whey hydrolyzate consists essentially of small peptides, in particular bi and tri-peptides.
  • the size of the molecules in the hydrolyzate can be modulated by microfiltration.
  • the hydrolyzate is obtained with a hydrolysis whose level is between 15 and 35%.
  • the rate can not be higher, for the moment, at 35% because above 35% the bitterness is so pronounced that it can not be controlled and in addition the composition would have more free amino acids than active biopeptides which could cause loss of effectiveness and control of treatment.
  • Alpha lactalbumin is a nutritional active component of whey particularly rich in tryptophan and branched amino acids.
  • Milk calcium is a calcium extracted from milk and retains a therapeutic action superior to synthetic calcium due to the residual presence of small bioactive peptides.
  • AMPK and / or MAPK and / or PPAR cycle regulator a and ⁇ and / or SIRT1 means any molecule or mixture of molecules acting on at least one of the AMPK and / or MAPK and / or PPAR cycles a and y and / or or SIRT1. It could be :
  • the composition may contain one or more tocopherol (s), or vitamin B6, or leucine, or one or more acid (s) amino (s) plugged (s), or a mixture of at least two of these molecules
  • the composition may comprise metformin, or one or more statins, or a mixture of metformin and statin (s).
  • the regulator AMPK cycles and / or MAPK and / or PPAR and y and / or SIRT1 is preferably a mimetic or agonist thiazolinediones.
  • thiazolinediones mimetic is meant a molecule or mixture of molecules that fully copies the mode of action of thiazolinediones because of its similar chemical structure, but as much as possible without the disadvantages.
  • thiazolinediones means a molecule or mixture of molecules which acts in the same way as the thiazolinediones, but as much as possible without the disadvantages.
  • Thiazolinediones have the advantage of acting in particular as a regulator with a powerful action of PPARy and AMPK cycles and indirectly on SIRT1. This action mimics a caloric restriction accompanied by a physical activity.
  • the thiazolinediones mimetic or agonist is chosen from the family of tocopherols or vitamin B6 or leucine or from the family of branched amino acids. If it is tocopherol, it should preferably be a mixture of ⁇ and ⁇ tocopherol, even more preferably in proportions of 75% for ⁇ and 25% for ⁇ .
  • composition according to the invention may optionally contain one or more active pharmaceutical ingredient (s) activator (s) AMPK cycles and / or MAPK and / or PPAR a and ⁇ and / or SIRTl, chosen from the metformin and statins, including simvastatin because of its workability, but also atorvastatin, pravastatin, rosuvastatin, fluvastatin or lovastatin or a mixture of at least two of these statins.
  • active pharmaceutical ingredient s
  • activator s
  • AMPK cycles and / or MAPK and / or PPAR a and ⁇ and / or SIRTl
  • metformin and statins including simvastatin because of its workability, but also atorvastatin, pravastatin, rosuvastatin, fluvastatin or lovastatin or a mixture of at least two of these statins.
  • the amount of active pharmaceutical ingredient (s) regulator (s) AMPK cycles and / or MAPK and / or PPAR and Y and / or SIRTl is 200 to 700 mg for metformin and 2.5 to 10 mg for statins, for between 20 and 40 g of composition without excipients.
  • the different constituents of the composition act in synergy for a very effective action.
  • composition according to the invention is in particular capable of acting on the level of adiponectin.
  • Adiponectin is a molecule produced in particular by adipocytes of visceral adipose tissue. It acts at the peripheral level by two receivers through which it regulates the AMPK, MAPK, PPARa, PPARy, SIRT1 cycles and inhibits the N FKB signal.
  • adiponectin is itself dependent on several factors, including AMPK, MAPK, PPAR and SIRT1: a dephosphorylation of ⁇ , MAPK, PPAR and / or SIRT1 leads to a decrease in the secretion of adiponectin.
  • AMPK AMPK
  • MAPK MAPK
  • PPAR PPAR
  • SIRT1 SIRT1
  • ROS reactive oxygen species
  • RNS reactive nitrogen species
  • LPS lipopolysaccharide
  • HDL high density lipoprotein
  • HMV High Molecular Weight
  • adiponectin is very low in people with cardiometabolic risk, but also in obese insulin resistance, diabetics, people with lipodystrophy, people with fatty liver, NAFLD, NASH, people with hypertension and people with coronary artery disease.
  • Adiponectin is deficient in particular because of the increase of inflammatory adipocytokines, in particular TNF ⁇ , which act negatively through the transcription, translation and turnover of AMPK, MAPK, PPAR and SIRT1, causing their decrease by dephosphorylation and therefore a decrease in the secretion of adiponectin.
  • composition according to the invention makes it possible to increase the rate of circulating adiponectin and / or to regulate its secretion in the long term.
  • the presence of at least one regulator of the AMPK and / or MAPK and / or PPAR ⁇ and ⁇ and / or SIRT1 cycles makes it possible to activate AMPK and / or MAPK and / or PPAR has and ⁇ and / or SIRT1 and therefore to increase the level of adiponectin.
  • Milk calcium also increases the level of adiponectin, especially adiponectin HMW.
  • composition according to the invention is capable of acting on the level of serotonin.
  • Serotonin is a hormone that acts in particular on mood and depression, stress, sleep, food intake and deviant eating behavior such as bulimia. It is mainly found in the intestine in the chromaffin cells, but also in the platelets and in the brain.
  • the precursor of serotonin is tryptophan, which is transformed into 5HTP and then into 5HT, serotonin. Its metabolites are 5-HIAA (5-hydroxy-indol-acetic), 5-HTOL (5-hydroxy-tryptophol) and its derivatives N-acetyl-5HT and melatonin.
  • Metabolic syndrome and abdominal overweight result in serotonin deficiency. It is the inflammation of adipocytokines that leads to the breakdown of serotonin into 5HIAA in the liver. In fact, inflammation favors the kynurenic pathway.
  • the composition according to the invention makes it possible to increase the level of serotonin, in particular thanks to the tryptophan provided in particular by the whey hydrolyzate and the alpha lactalbumin, but also by the reduction of the inflammation.
  • Tryptophan should preferably represent between 6 and 9%, more preferably approximately 7% by weight of the neutral amino acids present in the composition. This particular proportion ensures that an appropriate amount of tryptophan can cross the brain barrier to be converted to serotonin.
  • the daily tryptophan intake by the composition according to the invention is preferably, for people with metabolic syndrome or pre-diabetes stage, at least 0.5 g, preferably from 0.5 to 0.8 g.
  • composition according to the invention makes it possible to supply a large quantity of high quality amino acids, in particular leucine and isoleucine, in addition to the tryptophan already mentioned.
  • Leucine is particularly capable of acting on SIRT1, AMPK and PPARy and therefore allows an increase in adiponectin.
  • hydroxybutirate the active metabolite of leucine, regulates the ⁇ -oxidation of lipids through AMPK and SIRT1.
  • the leucine can come from whey hydrolyzate and alpha lactalbumin, and it can also be used alone, as a regulator of AMPK cycles and / or MAPK and / or PPAR a and ⁇ and / or SIRT1.
  • Isoleucine induces a decrease in blood glucose by increasing the use of glucose through AMPK in particular.
  • the ratio of the weight of leucine / total amino acids of the composition is preferably between 10 and 15%, the weight ratio of leucine / neutral amino acids of the composition is preferably between 30 and 40%, and the ratio by weight of leucine / branched acids of the composition is preferably between 45 and 55%.
  • the daily intake of leucine by the composition according to the invention is preferably at least 5 g.
  • the ratio by weight of isoleucine / total amino acids of the composition is preferably between 5 and 10%
  • the ratio by weight of isoleucine / neutral amino acids of the composition is preferably between 15 and 25%
  • the ratio by weight of isoleucine / branched acids of the composition is preferably between 20 and 30%.
  • the daily intake of isoleucine by the composition according to the invention is preferably at least 2.5 g.
  • Tryptophan, leucine and isoleucine are contained in the particular whey hydrolyzate used and in alpha lactalbumin.
  • the choice of these two compounds is essential for the effect of the composition.
  • dairy whey proteins are more suitable than plant proteins which have fewer branched amino acids or the fermentation amino acids of biotechnology which have a lower activity than the amino acids of whey because of the absence of active biopeptides.
  • the shape of the whey is important that digestibility and therefore the availability of amino acids is different and plays on the chronobiology of the intake according to whether one uses concentrate, isolate or hydrolyzate.
  • the best effects to meet the objective of the invention are obtained with a hydrolyzate containing small molecules, in particular bi and tri peptides which highlight whey biopeptides.
  • the molecules of the hydrolyzate must have a size of between 200 and 5000 daltons which represent the optimum presence of whey biopeptides which are disengaged from the macro peptides.
  • For still optimized efficiency at least 55% of the total molecules of the whey hydrolyzate has a molecular weight less than or equal to 1000 daltons which corresponds to a peptide of 6 amino acids maximum.
  • alpha lactalbumin is necessary in the composition according to the invention, because the use of a whey hydrolyzate alone, even of excellent quality, is not sufficient to provide the necessary proportions and amounts of certain amino acids, especially tryptophan, leucine and isoleucine.
  • alpha lactalbumin like milk calcium, can reduce the bitterness of whey, especially in the case of hydrolysis with a rate of between 15% and 35% which increases this bitterness.
  • the alpha lactalbumin is, very preferably, present in a proportion less than or equal to 50% by weight relative to whey.
  • the ratio by weight of protein between alpha lactalbumin and the hydrolyzate is between 50/50 and 30/70.
  • the hydrolyzate mixture of lactoserum and alpha lactalbumin of the composition according to the invention should therefore preferably contain at least tryptophan, leucine and isoleucine. Even more preferentially it also contains glutamine and arginine.
  • the presence of glutamine or glutamic acid reduces the hyperpermeability of the intestinal barrier.
  • the hyperpermeability of the intestinal barrier through the passage of LPS, is involved in the activation of the N FKB signal and thus in the decrease of adiponectin and especially the increase of inflammatory adipocytokines like IL6 and TNFa.
  • the action of glutamine or glutamic acid is enhanced by the presence of leucine and arginine.
  • glutamine and / or glutamic acid represent more than 150% of the weight of the leucine present in the composition.
  • glutamine and / or glutamic acid preferably represent by weight at least 7 times arginine.
  • composition may also contain other amino acids such as valine, phenylalanine or tyrosine in particular.
  • the mixture of principles active ingredients of the composition according to the invention may comprise one or more elements added freely chosen in particular from vitamin B9 and vitamin D.
  • the composition may contain essential fatty acids, in particular omega 3s.
  • omega 3 of plant origin ALA (alpha-linolenic acid), with a high proportion of EPA (eicosapentaenoic acid). or directly from purified EPA.
  • metformin has the advantage of acting through AMPK to inhibit hepatic glycogenesis, and improves endothelial dysfunction, but is associated with many side effects that disrupt treatment such as nausea and vomiting and in the worst case lactic acidosis.
  • These intolerances can be caused in particular by a renal insufficiency but also by the mutation of the transporter gene OCT1 which causes a saturation of metformin with concentrations of 30 ⁇ 19 ng / ml whereas the daily doses of the drug were normal of 1 to 3g / day .
  • the presence of the other constituents of the composition according to the invention makes it possible to be able to lower the activator doses of the AMPK and / or MAPK and / or PPAR ⁇ and ⁇ and / or SIRT1 cycles, in particular of metformin while retaining the same activity. but without side effects.
  • the daily dose of metformin in the composition according to the invention is less than or equal to 1 g, preferably between 500 mg and 1 g.
  • the composition may also contain additional constituents known to improve the adaptation of the AMPK, MAPK, PPAR and SIRT1 cycles such as zinc, chromium, curcumin, SOD, catalase, glutathione, resveratrol and or anthocyanins.
  • Curcumin at a low dose so as not to reach its pro-oxidant threshold, reduces the hyperpermeability of the intestinal barrier such as glutamine.
  • SOD, catalase and glutathione by their powerful antioxidant role, attack the ROS and indirectly modulate the N FKB signal of inflammation and therefore participate in an increase in the secretion of adiponectin.
  • SOD also acts on the prevention of ⁇ -oxidation of LDL.
  • Resveratrol, anthocyanins and curcumin act at the level of PPAR and AM PK.
  • the various constituents of the composition according to the invention act in synergy to provide surprising effects particularly adapted to the prevention of cardiometabolic risk and hepatic steatosis and to the treatment of the state of pre-diabetes.
  • the mixture of active ingredients of the composition according to the invention comprises at least:
  • composition may also contain freely added elements, such as vitamins and minerals, in addition to the native components of the hydrolyzate, alpha lactalbumin, or the regulators of the AM PK and / or MAPK cycles and / or PPAR a and ⁇ and / or SI RT1.
  • freely added elements such as vitamins and minerals, in addition to the native components of the hydrolyzate, alpha lactalbumin, or the regulators of the AM PK and / or MAPK cycles and / or PPAR a and ⁇ and / or SI RT1.
  • composition according to the invention is preferably constituted by at least:
  • the percentages being given, by weight of dry matter, of all the active ingredients present in the composition (apart from any excipients), a part of the constituents originating from the hydrolyzate, alpha lactalbumin or AMPK cycle regulator (s). and / or MAPK and / or PPAR a and ⁇ and / or SIRT1 and milk calcium and the remainder being freely added in the form of vitamins, minerals and fatty acids.
  • the mixture of active ingredients of the composition according to the invention comprises at least:
  • SIRT1 chosen from the family of tocopherols, vitamin B6, leucine, the family of branched amino acids, for between 20 and 40 g of composition composition without excipients, and
  • composition may also contain freely added elements, such as vitamins and minerals, in addition to the native components of the hydrolyzate, alpha lactalbumin, AMPK and / or MAPK cycle regulator (s) and / or or PPAR a and ⁇ and / or SIRT1.
  • freely added elements such as vitamins and minerals, in addition to the native components of the hydrolyzate, alpha lactalbumin, AMPK and / or MAPK cycle regulator (s) and / or or PPAR a and ⁇ and / or SIRT1.
  • composition according to the invention may consist of at least:
  • the branched amino acids of the above variant compositions consist of leucine, isoleucine and valine, preferentially:
  • composition according to the invention can be obtained by a process as described below:
  • obtaining a first mixture by mixing the constituents in the following order: whey hydrolyzate, alpha lactalbumin and milk calcium; the pH should be around 7 and stabilized at this level,
  • composition may be supplemented with conventional excipients and fillers known to those skilled in the art.
  • a powder is thus obtained which can be converted into a tablet or liquid, or used in its powder form in sachets, sticks, cans or capsules, for example.
  • it is in the form of powder or granules packaged in a bag to be diluted in water. It can also be in the form of ready-to-use beverage, food bars or extruded bars.
  • composition according to the invention when it is administered orally in sufficient quantity, allows in particular:
  • composition according to the invention make it possible in particular to increase the secretion of adiponectin and serotonin, to reduce inflammatory adipocytokines and insulin resistance for an action on the loss of visceral fat, liver fat and fat under -cutaneous deep.
  • composition according to the invention acts as an appetite suppressant and provides a feeling of satiety thanks to the increase of the rate of serotonin, and by the action of branched amino acids and milk calcium.
  • the composition according to the invention also makes it possible to lose visceral fat for a long time, in particular by:
  • composition according to the invention is also capable of acting on many other factors of cardiometabolic risk.
  • it is able to reduce stress, normalize blood pressure, reduce IL6 inflammation, TNFa, PAI-1 and CRP ultrasensitive, limit clotting (fibrinogen), regulate cholesterol and triglycerides, to reduce blood glucose and postprandial glucose, insulinemia and, more generally, to regulate cell energy cycles by regulating the APM / TP ratio through the AMPK, MAPK, PPAR a and ⁇ cycles and SIRT1.
  • the invention therefore relates to the composition as described above for its application as a health product, in particular as a medicament or as an oral medical nutrition product for the prevention of cardiometabolic risk and / or for the prevention of hepatic steatosis and / or for the prevention and / or treatment of the state of type II pre-diabetes (and thus fight against the onset of type II diabetes), type II diabetes, cardiometabolic diseases and / or infertility and / or sub-fertility in humans.
  • composition according to the invention can be used as a health product to reduce visceral fat and deep subcutaneous fat in people overweight.
  • the health product can specifically be used to decrease visceral fat and deep subcutaneous fat in overweight and / or to reduce waist circumference and / or reduce stress and / or normalize blood pressure and / or or to limit the oxidation and / or decrease the ultrasensitive CRP inflammation and / or to limit coagulation and / or to regulate cholesterol and triglycerides and / or to lower blood glucose and blood sugar post prandial and / or insulinemia and / or decrease hypersensitivity of the intestinal barrier and / or rebalance the intestinal flora and / or fight against type II diabetes.
  • composition according to the invention is preferably between 40 and 80 g, more preferably in two doses of between 20 and 40 g distributed a time (usually 1 hour) before lunch and the other before dinner.
  • the bioavailability in the body of the amino acids, peptides and proteins present in the composition is between 10 and 30 minutes, which allows a rapid action to trigger satiety so as to limit the amount of food to be taken during the meal next .
  • the presence of milk calcium, with alpha lactalbumin improve the palatability of the dietary product according to the invention by masking in particular the bitter taste of the whey hydrolyzate, so that they participate in removing the risk that people will stop eating it for reasons of taste and abandon their diet before its end.
  • the combination of fatty acids, in particular EPA, with the milk calcium and the particular amino acid mixture according to the invention and the released biopeptides also makes it possible to slow down the transformation of the preadipocytes into visceral adipocytes by regulation of PCM. -1 ("Monocyte chemoattractant protein 1"), to limit the action of macrophages visceral adipose tissue and accelerate lipolysis of visceral adipocytes.
  • PCM. -1 Monocyte chemoattractant protein 1
  • the invention also allows:
  • composition can therefore be used as an oral health product, acting:
  • composition according to the invention in particular the variant containing metformin and / or statins, can be used in particular as a medicament for the treatment of metabolic syndrome and the prevention and / or treatment of cardiometabolic diseases.
  • a composition makes it possible to treat the metabolic syndrome by decreasing visceral fat, liver fat and deep subcutaneous fat, in particular by increasing the level of adiponectin and serotonin.
  • the combined presence of at least one activating pharmaceutical active ingredient of the AMPK, MAPK, PPAR ⁇ and ⁇ and / or SIRT1 cycles, and at least one nutritional regulator of the AMPK, MAPK, PPAR ⁇ and ⁇ cycles and or SIRT1 activates AMPK, MAPK, PPARa, PPARy and / or SIRT1 and thus increases the level of adiponectin.
  • composition according to the invention can be used as a health product, especially as a medicament for prevention and primary, secondary and tertiary treatment of cardiometabolic diseases.
  • a health product especially as a medicament for prevention and primary, secondary and tertiary treatment of cardiometabolic diseases.
  • it can be used to fight cardiometabolic risk factors but also cardiometabolic diseases including:
  • cardiovascular diseases such as hypertension, arteritis of the lower limbs, coronary heart disease, after-effects of infarction or cerebral stroke,
  • hyperlipidemia and in particular hyperlipidemia of type II diabetes
  • composition variant containing metformin and / or one or more statin (s) makes it possible to synergize the pharmacological effects of the active principle (s) active (s) pharmaceutical (s) and the same effects of the active ingredients nutritional such as amino acids and small active biopeptides contained in whey hydrolyzate and alpha lactalbumin as well as nutritional regulators of AMPK and / or MAPK and / or PPAR cycles a and ⁇ and / or SIRT1, and calcium of milk.
  • the composition according to the invention thus makes it possible to preserve and even increase the effectiveness of the treatment by reducing the doses of the pharmaceutical active ingredient (s) in order to minimize or cancel their undesirable side effects.
  • the activating pharmaceutical active ingredients of the AMPK, MAPK, PPAR ⁇ and ⁇ and / or SIRT1 cycles are known to increase the level of adiponectin, but at doses causing significant adverse effects, in particular myalgias. muscle for statins and manifestations ranging from simple stomach upset to lactic acidosis, which can be fatal, to nausea and vomiting for metformin.
  • composition according to the invention in particular the variant containing metformin and / or one or more statin (s), also makes it possible to improve fertility in overweight men and women, in particular in persons at risk.
  • cardiometabolic in particular increasing the rate of adiponectin, to decrease the inflammatory adipocytokines and the insulin resistance which are the triggering factors of this infertility and / or under fertility, in particular the syndrome of the polykistic ovaries in the woman and the quantity and quality of the sperm in the man.
  • composition allows the treatment of infertility and sub-fertility in general, in particular infertility or sub-fertility in men or women with a decrease in adiponectin and / or an increase in inflammatory adipocytokines and insulinemia.
  • the invention is specifically directed to the use of the composition as a medicament for the treatment of infertility or sub-fertility in men or women with: - a waist circumference outside the IDF 2005 standards (80/94 cm), and / or
  • composition can be used in particular:
  • composition according to the invention is particularly suitable for the treatment of metabolic infertility or metabolic sub-fertility.
  • metabolic infertility or metabolic sub-fertility means infertility or sub-fertility so the cause is a metabolic dysfunction that results in a metabolic syndrome in particular a waist circumference above international standards and / or insulin resistance or type II diabetes and / or dyslipidemia and / or hepatic steatosis and / or low grade chronic inflammation and / or an anxiety or depressive state.
  • This metabolic infertility is clinically translated by polykistic ovaries, endometriosis, anovulation, dysovulation, oligozoospermia, asthenozoospermia or erectile dysfunction.
  • compositions act in synergy for a very effective action on the improvement of fertility in men or women, in particular in men or women with a metabolic syndrome.
  • composition according to the invention is in particular capable of acting on the level of adiponectin, inflammation and insulinemia.
  • the level of adiponectin is generally very low in infertile persons whereas the CRPus and TNFa levels are elevated insulin levels, especially in people with polykistic ovaries, endometriosis, oligozoospermia, asthenozoospermia or erectile dysfunction.
  • the disruption of adiponectin levels or of its mechanism of action caused by inflammation is associated with a disturbance of fertility and fertility.
  • adipocytokines is essential for the maintenance of the integrity of the hypothalamic-pituitary-ovarian axis, ovulation, successful nesting and the course of pregnancy.
  • Adiponectin is positively bound with SHBG and negatively with testosterone and TNFa.
  • the reproductive system is coupled with energy balance.
  • AMPK and PPAR ⁇ and ⁇ play a major role in intervening in the regulation of ovarian function in women, since they regulate steroidogenesis of granulosa cells and oocyte maturation.
  • Some hormones involved in metabolism use AMPK as a signal molecule to transmit their central and ovarian effects on reproductive function. Disruption of this system is at the origin of pathologies such as polykistic ovary syndrome and endometriosis.
  • an action on testosterone a decrease in women in polykistic ovaries and an increase in men in sub-fertility or metabolic infertility.
  • composition according to the invention is capable of acting on the level of serotonin.
  • women with polykistic ovarian syndrome also have a low level of serotonin.
  • Men with infertility due to a metabolic syndrome or diabetes or who have continuous erectile dysfunction may have a low serotonin level of less than 80 ng / ml responsible for oligospermia.
  • composition according to the invention in particular the composition variant comprising metformin and / or one or more statin (s), can be used specifically as a health product, in particular as a medicament, for the prevention of atherosclerosis.
  • Atherosclerosis is characterized by a deposit of lipids on the intima of the arteries forming a nucleus which fills with fibers of lipid deposits, foam cells and finally macrophages that secrete adipocytokines.
  • the final phase is calcification of the atheroma plaque.
  • the genesis of atherosclerosis is the same as that of the metabolic syndrome; these include excess cholesterol, triglycerides, hypertension, abdominal obesity, type II diabetes, smoking, chronic stress, sedentary lifestyle, pollution, and family history. There is therefore a great similarity between atherosclerosis and the metabolic syndrome, although the consequence of atherosclerosis may be a single dyslipidemia related to inflammation.
  • Adiponectin The level of adiponectin is very low and the levels of inflammation and insulinemia are high in people with atherosclerosis. Adiponectin is deficient in particular because of the increase of inflammatory adipocytokines, in particular TNFa, which act negatively through the transcription, translation and turnover of AMPK, MAPK, PPAR and SIRT1, causing their decrease by dephosphorylation and therefore a decrease in the secretion of adiponectin.
  • composition according to the invention makes it possible to increase the rate of circulating adiponectin and / or to regulate its secretion in the long term.
  • composition according to the invention is capable of acting on the level of serotonin.
  • the invention also allows: to prevent the formation and rupture of atheroma plaques, in particular by significantly decreasing the secretion of inflammatory adipocytokines, in particular CRP us, so as to prevent cardiovascular events,
  • composition according to the invention can therefore be used as a health product for different therapeutic applications.
  • composition comprising a mixture of active ingredients consisting of at least:
  • whey hydrolyzate with a molecular weight of between 200 and 5,000 daltons
  • At least one regulator of the AMPK and / or MAPK and / or PPAR ⁇ and ⁇ and / or SIRT1 cycles chosen from the tocopherol family, vitamin B6, leucine and the branched amino acid family, and
  • ⁇ о ⁇ ение may be used preferentially to prevent cardiometabolic risk, to prevent hepatic steatosis and / or to treat pre-diabetes and type II diabetes, particularly as a medical nutrition product.
  • composition comprising a mixture of active ingredients consisting of at least:
  • whey hydrolyzate with a molecular weight of between 200 and 5,000 daltons
  • At least one regulator of the AMPK and / or MAPK and / or PPAR ⁇ and ⁇ and / or SIRT1 cycles may be used preferentially to prevent cardiometabolic risk, prevent and / or treat hepatic steatosis and / or prevent and / or treat pre-diabetes and type II diabetes, prevent and / or treat cardiovascular disease, prevent and / or treat infertility or sub-fertility, prevent atherosclerosis, especially as a drug.
  • the invention is now illustrated by non-limiting examples of compositions in the form of a 40 g powder (active ingredients and excipients) packaged in a bag, suitable for use as a health product.
  • composition is obtained from the following active ingredients:
  • alpha lactalbumin including 12 g of proteins / peptides
  • vitamin E preferably in the form of a mixture of tocopherol
  • composition comprises in whey and alpha lactalbumin:
  • the product When administered twice a day (one sachet before lunch and one packet before dinner) for at least 120 days in patients with signs of cardiometabolic risk, the product is administered twice daily. waist circumference of about 5% compared to the initial waistline, which is characterized by a significant decrease in fat and in particular visceral and subcutaneous fat. Administration for 200 to 240 days, allows a loss of 10% of the waist compared to the initial waist.
  • the loss of fat mass is usually greater than the total weight loss which implies a relative increase in lean mass because it does not fall with the invention because of the composition and in particular branched amino acids and leucine.
  • the composition according to the invention makes it possible in particular to reduce visceral fat between 5 and 10%, depending on the treatment time, of the total starting weight, this reduction being significant of the reduction of the risk of cardiometabolic diseases. It is reflected in particular by:
  • Example 2 of composition and use for the prevention / treatment of pre diabetes, diabetes and sub-fertility and metabolic infertility
  • composition is obtained from the following active ingredients:
  • alpha lactalbumin including 12 g of proteins / peptides
  • vitamin E preferably in the form of a mixture of tocopherol
  • This composition comprises:
  • composition 2 for Pre-diabetes and Diabetes
  • the composition makes it possible in particular to reduce the visceral fat between 5 and 10%, depending on the treatment time, of the total starting weight, this reduction being significant of the reduction of the risk of diabetic diseases. It is reflected in particular by:
  • composition 2 for the Prevention and / or Treatment of Infertility or Sub-Fertility:
  • Example 2 When the composition of Example 2 is administered twice daily (one sachet before breakfast and one sachet before dinner) for at least 120 days, in patients presenting with signs associated with cardiometabolic risk, particular mention is made of a decrease in waist circumference of around 5% compared to the initial waist circumference, which characterized by a significant decrease in fat and in particular visceral and subcutaneous deep fat. Administration for 200 to 240 days, allows a loss of 10% of the waist compared to the initial waist. Fat loss is usually greater than total weight loss which implies a relative increase in lean body mass.
  • composition according to the invention makes it possible in particular to reduce visceral fat between 5 and 10% (depending on the treatment time) of the total starting weight, this reduction being significant of the reduction of the risk of sub-fertility and infertility, in particular. subfertility and metabolic infertility, and cardiometabolic diseases. It is reflected in particular by:
  • LH leukinizing hormone
  • Composition Example 3 and its Use for Secondary and Tertiary Primary Prevention and Treatment of Cardiovascular Diseases and Atherosclerosis
  • composition is obtained from the following active ingredients:
  • alpha lactalbumin including 12 g of proteins / peptides, - 5 mg of simvastatin,
  • vitamin E preferably in the form of a mixture of tocopherol
  • This composition comprises:
  • Composition 3 for the Prevention and Treatment of Cardiovascular Diseases
  • composition 3 for the Prevention of Atherosclerosis
  • normalization of systolic and diastolic blood pressure improvement of homeostasis factors such as fibrinogen, matrix remodeling with improved membrane elasticity, normalization of CRP us and plasma and adipocyte markers of inflammation increased adipocyte adipocyte and plasma serotonin increase.
  • composition is obtained from the following active ingredients:
  • alpha lactalbumin including 12 g of proteins / peptides
  • vitamin E preferably in the form of a mixture of tocopherol
  • This composition comprises:
  • Example 2 When administering the composition of Example 2 in a course of treatment twice a day (a sachet before lunch and a sachet before dinner) for at least 120 days, in patients presenting signs associated with atherosclerosis and / or at the dysfunction of the metabolic survivalillisme, one notes a decrease in the circumference of the order of 5% compared to the initial waistline, which is characterized by a significant decrease in fat and in particular visceral and subcutaneous deep fat. Administration for 200 to 240 days, allows a loss of 10% of the waist compared to the initial waist. Fat loss is usually greater than total weight loss which implies a relative increase in lean body mass.
  • composition according to the invention makes it possible in particular to reduce the visceral fat between 5 and 10%, depending on the treatment time, of the total starting weight, this reduction being significant of the reduction of the risks related to diabetes especially associated with high triglycerides which according to prevalence studies are the most dangerous associations for a cardiovascular event. It is reflected in particular by:
  • adipocyte and plasma adiponectin increase
  • composition according to the invention is accompanied by a change in lifestyle to further enhance its effects. Indeed, in chronic diseases, the problem is more complicated than in the case of an acute disease where it is usually enough to make the diagnosis, to formulate the treatment, to inform the patient and to follow through analyzes the treatment results and adapt it if necessary.
  • the composition according to the invention is therefore preferably used as a health product in addition to a change in lifestyle to support the treatment in the context of the increase in adiponectin and serotonin, the decrease in insulinemia and inflammation in particular.
  • composition according to the invention is preferably used as a health product in addition to:
  • the diet should in particular include a consumption of carbohydrates with a low glycemic load (or glycemic index) in general of less than 20 and / or a consumption of soluble and insoluble fibers and / or a suppression of saturated fatty acids and the partial replacement of these acids.
  • the goal of such a diet is to limit postprandial blood glucose and related inflammation peaks that cause cardiovascular events, to limit the excessive oxidation of carbohydrates, to lower the inflammation of adipocytokines, to stop from the transformation of preadipocytes into adipocytes and the infiltration of macrophages and finally the lipolysis of visceral adipocytes.
  • the drastic limitation of the glycation products makes it possible to lower the inflammation, this requires a change that is often radical in the cooking methods, in particular fried foods.
  • the intake of omega 3 and non-fat animal protein from fish and white meat can also promote lipolysis especially in the liver. In addition, it significantly increases adiponectin.
  • caloric restriction it increases SIRT1 and therefore promotes an increase in adiponectin levels.
  • the management of chronic stress is preferably carried out by holistic methods or specific or general physical activities to lower the circulating cortisol. This chronic stress management has an impact on AMPK, MAPK, PPARy and SIRTl.
  • the management of the anxious or depressive tendency can be achieved by holistic methods or specific or general physical activities.
  • the intake of tryptophan and therefore serotonin can improve the anxiety or depressive background common to many overweight people.
  • the production of cerebral serotonin the quality of sleep is improved.
  • weight loss and fat mass sleep apnea often disappear.
  • Caloric restriction and increased physical activity act on the AMPK, PPAR and SIRT1 cycles in a significant way and conversely, the biochemical increase of AMPK, PPAR and SIRT1 mimics the action of caloric restriction and physical activity. This is why the combination of a composition capable of increasing AMPK, PPAR and SIRTl, and a caloric restriction associated with physical activity has an extremely favorable impact on the prevention of cardiometabolic and steatosis risk factors. hepatic and pre diabetes treatment.
  • composition supplemented by a change in lifestyle requires self-management of the patient which requires in particular a therapeutic education of the patient.
  • the use of the health product composition is accompanied by a process comprising in particular:
  • Therapeutic patient education requires two conditions:
  • Patient motivation in the health setting is difficult to implement when it comes to lifestyle change, especially if it is aimed at a change of more than 20% of habits that are rooted in the patient's personality (family, region, religion, social milieu, professional environment, etc.).
  • the use of the composition as a health product is also accompanied by the determination of a waistline reduction target.
  • the difficulty lies in the number of people concerned, since the metabolic syndrome affects 25 to 35% of the adult population is millions of people.
  • the medical and paramedical structures are not capable of forming such a mass of population. It is therefore preferable to use e-health in a personalized way but also standardized by phenotypes because the contact must be frequent, ideally every day.
  • the use of the composition as a health product is also accompanied by training the patient in a lifestyle change by example and by training effect.
  • the use of the composition as a health product can be accompanied by a therapeutic e-health teaching, in particular by the use of a medical video game in which an avatar of the patient evolves as his model.
  • the patient provides information on their medical data and evolutions, as well as information on the health product's intake, diet, caloric restriction, chronic stress, depressive tendency and pharmacological medication if necessary.
  • the avatar reacts like the patient who will then receive messages according to his positive or negative evolution. Each evolution of the avatar is explained with a teaching on the positive or negative points.
  • the invention therefore also relates to the use of the composition as a health product accompanied by a method of therapeutic education including in particular: - the motivation of the patient by the determination of a waistline reduction target, and / or

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to a composition suitable for use as a health product, comprising a mixture of active ingredients made up of at least: - a lactoserum hydrolysate with a molecular weight comprised between 200 and 5000 daltons, - alpha-lactalbumin, - at least one AMPK, MAPK, PPAR and/or SIRT1 cycle regulator, - milk calcium. It is particularly useful as a medical nutrition product or orally administered drug, to prevent and/or combat various diseases.

Description

COMPOSITION INTERVENANT DANS LA REGULATION DU DYSFONCTIONNEMENT DES CYCLES DE L'ENERGIE, DE L'INFLAMMATION ET DE L'INSULINORESISTANCE ET SON UTILISATION NOTAMMENT DANS LES MALADIES CARDIOMETABOLIQUES  COMPOSITION INVOLVED IN REGULATING THE DYSFUNCTION OF CYCLES IN ENERGY, INFLAMMATION AND INSULIN RESISTANCE AND ITS USE IN PARTICULAR IN CARDIOMETABOLIC DISEASES
La présente invention concerne une composition spécifique et son utilisation comme produit de santé en particulier pour la prévention du risque cardiométabolique, pour la prévention et le traitement de maladies cardiométaboliques, et pour la prévention et le traitement de l'infertilité et/ou de la sous-fertilité des personnes en surpoids. The present invention relates to a specific composition and its use as a health product especially for the prevention of cardiometabolic risk, for the prevention and treatment of cardiometabolic diseases, and for the prevention and treatment of infertility and / or -fertility of overweight people.
Le syndrome métabolique ou risque cardiométabolique désigne la présence chez un individu de plusieurs signes cliniques et biologiques qui démontrent le début de maladies cardiaques et de diabète de type II, sans que toutefois ces signes ne soient forcément ressentis par la personne atteinte. Il se caractérise par l'association de plusieurs manifestations, en particulier un périmètre abdominal important et/ou un taux élevé de triglycérides dans le sang et/ou une augmentation de l'intolérance au glucose (glycémie élevée) et/ou une insulinorésistance et/ou une hypertension artérielle et/ou un taux de HDL abaissé et/ou une augmentation du fibrinogène et/ou des adipocytokines inflammatoires : TNFa (« Tumor Necrosis Factor a » facteur de nécrose tumorale a) , IL6 (Interleukine 6), PAI-1 (« Plasminogen activator inhibitor-1 » inhibiteur de l'activateur plasminogène-1), CRP (« C- reactive protéin e protéine C réactive) ultrasensible, qui provoquent une baisse de l'adiponectine et de la sérotonine qui sont des hormones centrales dans ce type de dysfonctionnement. Metabolic syndrome, or cardiometabolic risk, refers to the presence in an individual of several clinical and biological signs that indicate the onset of heart disease and type II diabetes, although these signs are not necessarily felt by the person affected. It is characterized by the association of several manifestations, in particular an important abdominal perimeter and / or a high level of triglycerides in the blood and / or an increase in glucose intolerance (high blood sugar) and / or insulin resistance and / or or decreased arterial hypertension and / or HDL and / or increased fibrinogen and / or inflammatory adipocytokines: TNFa ("Tumor Necrosis Factor a" tumor necrosis factor a), IL6 (Interleukin 6), PAI-1 ("Plasminogen activator inhibitor-1" activator inhibitor plasminogen-1), CRP ("C-reactive protein C-reactive protein) ultrasensitive, which cause a decrease in adiponectin and serotonin which are central hormones in this type of dysfunction.
Le risque d'anomalies métaboliques et cardiovasculaires est corrélé à une surcharge pondérale et dans la plupart des cas à une mauvaise hygiène de vie. Néanmoins, toutes les surcharges pondérales n'induisent pas nécessairement de risques vitaux pour la santé. En effet, les problèmes cardiométaboliques sont liés au gras viscéral, c'est-à-dire le gras profond autour de la taille, et au gras sous-cutané profond. La graisse sous-cutanée des deux premières couches, si elle est inesthétique, ne pose pas de problème de santé en soi. La graisse viscérale et la graisse de la couche profonde sous-cutanée, contiennent des macrophages très actifs d'un point de vue hormonal, qui entraînent des dysfonctionnements du foie, du pancréas et du système de régulation énergétique au niveau de la cellule, du cerveau et de l'intestin, ainsi que de nombreuses déficiences provoquées par l'inflammation légère et chronique de l'organisme qui est le problème central de ce type de maladies chroniques. Cette inflammation chronique est à l'origine de la formation de plaques de gras dans les vaisseaux, qui se déposent sur les parois (angine de poitrine et artérite des membres inférieurs) et finissent par se rompre (infarctus et AVC) par l'action d'une des adipocytokines de l'inflammation la CRPus (protéine réactive C ultra-sensible). En outre, les radicaux libres, de par la formation de leur déchets, gênent les échanges au niveau des cellules provoquant l'intolérance au glucose, une insulino résistance puis le diabète par un remodelage matriciel de la cellule. The risk of metabolic and cardiovascular abnormalities is correlated with being overweight and in most cases with an unhealthy lifestyle. Nevertheless, not all weight surges necessarily lead to life-threatening health risks. Indeed, cardiometabolic problems are related to visceral fat, that is to say deep fat around the waist, and deep subcutaneous fat. The subcutaneous fat of the first two layers, if unsightly, does not pose a health problem in itself. The visceral fat and the fat of the deep subcutaneous layer, contain macrophages very active from a hormonal point of view, which cause dysfunctions of the liver, the pancreas and the system of energy regulation at the level of the cell, the brain and intestine, as well as many impairments caused by mild and chronic inflammation of the body which is the central problem of this type of chronic diseases. This chronic inflammation is responsible for the formation of fatty plaques in the vessels, which are deposited on the walls (angina pectoris and arteritis of the lower limbs) and eventually rupture (infarction and stroke) by the action of one of the adipocytokines of inflammation the CRPus (ultra-sensitive reactive protein C). In addition, free radicals, by the formation of their waste, interfere with the exchanges at the level of the cells causing intolerance to glucose, an insulin resistance and diabetes by a matrix remodeling of the cell.
Par ailleurs, le foie est particulièrement sensible au syndrome métabolique puisqu'il est le premier lieu de dépôt des triglycérides et avec l'augmentation du stockage se produit une stéatose hépatique qui peut évoluer en NAFLD (« Nonalcoholic Fatty Liver Disease » stéatose hépatique non alcoolique), NASH (« Nonalcoholic Steatohepatitis » stéatohépatite non alcoolique) avec une fibrose plus ou moins importante et évolutive vers la cirrhose et le cancer. In addition, the liver is particularly sensitive to the metabolic syndrome since it is the first place of deposit of triglycerides and with the increase in storage occurs a fatty liver that can evolve into NAFLD (Nonalcoholic Fatty Liver Disease non-alcoholic fatty liver disease ), NASH ("nonalcoholic steatohepatitis" nonalcoholic steatohepatitis) with fibrosis more or less important and progressive to cirrhosis and cancer.
Il est donc nécessaire de trouver des solutions permettant de prévenir le risque cardiométabolique, en particulier des traitements permettant de prévenir la stéatose hépatique et de bloquer le passage du pré diabète en diabète de type II en faisant baisser la glycémie et en normalisant les facteurs de risque comme l'hyperlipidémie, l'hypertension, l'hyperglycémie et l'hyper insulinémie, pour retarder ou enrayer les maladies cardiovasculaires.  It is therefore necessary to find solutions to prevent cardiometabolic risk, in particular treatments to prevent fatty liver and to block the transition from pre-diabetes to type II diabetes by lowering blood glucose and normalizing risk factors. such as hyperlipidemia, hypertension, hyperglycemia and hyper insulinemia, to delay or reverse cardiovascular disease.
Les solutions existantes pour prévenir le risque cardiométabolique sont généralement limitées à l'application de régimes alimentaires. Or, aucun de tous les régimes proposés depuis l'apparition du risque cardiométabolique dans les années 1990, qu'ils soient équilibrés, hyperprotéinés, hyperglucidiques, hyperlipidiques, très restrictifs ou déséquilibrés, n'a résolu les problèmes spécifiques des dysfonctionnements et des particularités pathologiques de ce syndrome. Les diètes protéinées très restrictives aggravent même les dysfonctionnements métaboliques et provoquent des effets rebonds. Par ailleurs, les médicaments existants utilisés agissent sur une des conséquences du syndrome métabolique comme l'hyperglycémie, l'hypertension, l'hypertriglycérémie ou l'hypercholestérolémie, mais pas sur l'ensemble du syndrome métabolique et même parfois aggravent une autre composante du syndrome métabolique (comme par exemple les produits actuels à base de statines qui conduisent à une diabétogènèse). Existing solutions to prevent cardiometabolic risk are usually limited to the application of diets. However, none of the diets proposed since the onset of cardiometabolic risk in the 1990s, whether balanced, hyperprotein, hyperglucidic, hyperlipidic, very restrictive or unbalanced, has solved the specific problems of dysfunction and pathological particularities. of this syndrome. The very restrictive protein diets aggravate even the metabolic dysfunctions and cause rebound effects. Moreover, the existing drugs used affect one of the consequences of the metabolic syndrome such as hyperglycemia, hypertension, hypertriglyceremia or hypercholesterolemia, but not on the whole metabolic syndrome and sometimes even aggravate another component of the metabolic syndrome (such as current statin-based products that lead to diabetogenesis).
Plus récemment, des produits diététiques destinés à diminuer le gras viscéral et sous-cutané profond ont été développés et utilisés pour la prévention du risque cardiométabolique. L'objectif de la présente invention est de proposer une solution différente agissant sur des voies spécifiques du syndrome métabolique, simple d'utilisation et efficace, qui soit capable de prévenir le risque cardiométabolique, de prévenir la stéatose hépatique et de traiter le pré diabète, mais également de traiter les maladies cardiovasculaires en général et de prévenir et traiter l'infertilité et la sous-fertilité chez l'homme et la femme. More recently, dietary products for lowering visceral and subcutaneous fat have been developed and used for the prevention of cardiometabolic risk. The objective of the present invention is to propose a different solution acting on specific pathways of the metabolic syndrome, easy to use and effective, which is capable of preventing cardiometabolic risk, preventing fatty liver and treating pre-diabetes, but also to treat cardiovascular diseases in general and to prevent and treat infertility and sub-fertility in men and women.
Pour y répondre, la présente invention propose d'agir à la fois sur le taux d'adiponectine, de sérotonine et d'apporter des acides aminés et des biopeptides actifs de petite taille, avec une action au niveau cellulaire sur le cycle de l'énergie AMP (adénosine monophosphate) et ATP (adénosine triphosphate) à travers l'ensemble des cycles AMPK (« AMP-activated protein kinase »), MAPK (« Mitogen-activated protein kinase »), PPAR (« peroxisome proliferator activated receptors ») et SIRTl (sirtuin 1), et sur les cycles de l'inflammation et de l'insulinorésistance. To answer this, the present invention proposes to act both on the adiponectin and serotonin levels and to provide amino acids and small active biopeptides, with an action at the cellular level on the cycle of the AMP (adenosine monophosphate) and ATP (adenosine triphosphate) energy through AMP-activated protein kinase (AMPK), MAPK ("mitogen-activated protein kinase"), PPAR ("peroxisome proliferator activated receptors") and SIRT1 (sirtuin 1), and on the cycles of inflammation and insulin resistance.
A cet effet, l'invention vise une composition adaptée pour une utilisation comme produit de santé à administration orale, en particulier comme produit de nutrition médicale ou médicament, comprenant un mélange de principes actifs constitué par au moins :  For this purpose, the invention provides a composition suitable for use as an oral health product, in particular as a medical or medicinal product, comprising a mixture of active ingredients consisting of at least:
- un hydrolysat de lactosérum de poids moléculaire compris entre 200 et 5000 daltons,  a whey hydrolyzate with a molecular weight of between 200 and 5,000 daltons,
- de l'alpha lactalbumine,  - alpha lactalbumin,
- au moins un régulateur des cycles AMPK et/ou MAPK et/ou PPAR a et γ et/ou SIRTl, en particulier un mimétique ou agoniste des thiazolinediones, choisi parmi la famille des tocophérols et la vitamine B6 et la leucine et la famille des acides aminés branchés, et  at least one regulator of the AMPK and / or MAPK and / or PPAR α and γ and / or SIRT1 cycles, in particular a thiazolinedione mimetic or agonist, chosen from the family of tocopherols and vitamin B6 and leucine and the family of branched amino acids, and
- du calcium de lait,  - milk calcium,
- et éventuellement au moins un principe actif pharmaceutique régulateur des cycles AMPK et/ou MAPK et/ou PPAR a et γ et/ou SIRTl, choisi parmi la metformine et les statines.  and optionally at least one AMPK and / or MAPK and / or PPAR and / or PPM and / or PPAR cycle active pharmaceutical ingredient chosen from metformin and statins.
Avantageusement, une telle composition permet de diminuer la graisse viscérale, la graisse hépatique et la graisse sous-cutanée profonde en permettant notamment une augmentation du taux d'adiponectine et de sérotonine. Elle peut être utilisée comme produit de santé notamment en prévention du risque cardiométabolique et/ou de la stéatose hépatique et/ou en prévention et/ou traitement du pré diabète (en évitant le passage du pré diabète en diabète de type II), du diabète de type II, de maladies cardiovasculaires et/ou de l'infertilité et/ou sous-fertilité chez l'homme ou la femme en surpoids. Elle intervient dans la régulation du dysfonctionnement des cycles de l'énergie, de l'inflammation et de l'insulinorésistance. Advantageously, such a composition makes it possible to reduce visceral fat, liver fat and deep subcutaneous fat, in particular by allowing an increase in adiponectin and serotonin levels. It can be used as a health product, particularly in the prevention of cardiometabolic risk and / or hepatic steatosis and / or in the prevention and / or treatment of pre-diabetes (avoiding the transition from pre-diabetes to type II diabetes), diabetes type II, cardiovascular disease and / or infertility and / or subfertility in overweight men or women. It is involved in the regulation of the dysfunction of energy cycles, inflammation and insulin resistance.
Préférentiellement, elle est utilisée en complément d'un changement de mode vie impliquant notamment une alimentation particulière, une restriction calorique, la pratique d'une activité physique, la gestion du stress chronique et la gestion d'un état anxieux nécessitant une éducation thérapeutique du patient.  Preferentially, it is used in addition to a life-style change involving, in particular, a particular diet, a caloric restriction, the practice of a physical activity, the management of chronic stress and the management of an anxiety state requiring a therapeutic education of the patient. patient.
L'invention est à présent décrite en détails. The invention is now described in detail.
L'invention vise donc une composition adaptée pour une utilisation comme produit de santé à administration orale, comprenant un mélange de principes actifs constitué par au moins :  The invention therefore relates to a composition adapted for use as an oral health product, comprising a mixture of active ingredients consisting of at least:
- un hydrolysat de lactosérum de poids moléculaire compris entre 200 et 5000 daltons,  a whey hydrolyzate with a molecular weight of between 200 and 5,000 daltons,
- de l'alpha lactalbumine,  - alpha lactalbumin,
- au moins un régulateur des cycles AMPK et/ou MAPK et/ou PPAR a et γ et/ou SIRT1, choisi parmi la famille des tocophérols, la vitamine B6, la leucine et la famille des acides aminés branchés, et  at least one regulator of the AMPK and / or MAPK and / or PPAR α and γ and / or SIRT1 cycles, chosen from the tocopherol family, vitamin B6, leucine and the branched amino acid family, and
- du calcium de lait.  - milk calcium.
Selon une variante, la composition peut également contenir en plus au moins un principe actif pharmaceutique régulateur des cycles AMPK et/ou MAPK et/ou PPAR a et γ et/ou According to one variant, the composition may also contain at least one active pharmaceutical ingredient that regulates AMPK and / or MAPK cycles and / or PPARs α and γ and / or
SIRT1, choisi parmi la metformine et les statines. SIRT1, selected from metformin and statins.
Par produit de santé au sens de l'invention, on entend tout produit agissant en faveur de la santé humaine, notamment un médicament ou un produit de nutrition médicale. By health product within the meaning of the invention is meant any product acting in favor of human health, including a drug or a medical nutrition product.
Par produit de nutrition médicale au sens de l'invention, on entend un aliment à vocation thérapeutique de prévention ou de traitement, utilisé seul ou associé à d'autres thérapies. By medical nutrition product within the meaning of the invention is meant a therapeutic food for prevention or treatment, used alone or in combination with other therapies.
La composition selon l'invention est particulièrement adaptée aux personnes qui souhaitent perdre du gras viscéral, du gras hépatique et/ou du gras sous-cutané en particulier pour des raisons médicales de prévention primaire ou secondaire ou tertiaires des maladies cardiovasculaires, de la stéatose hépatique, du pré diabète, du diabète et/ou de l'infertilité et/ou sous-fertilité. The composition according to the invention is particularly suitable for persons wishing to lose visceral fat, hepatic fat and / or subcutaneous fat, in particular for medical reasons of primary or secondary or tertiary prevention of diseases. cardiovascular, hepatic steatosis, pre-diabetes, diabetes and / or infertility and / or sub-fertility.
Par pré diabète on entend pré diabète de type II et ces termes sont utilisés indifféremment pour décrire la présente invention. De même, par diabète on entend diabète de type II et ces termes sont utilisés indifféremment pour décrire la présente invention  By pre diabetes is meant pre-type II diabetes and these terms are used interchangeably to describe the present invention. Similarly, diabetes is defined as type II diabetes and these terms are used interchangeably to describe the present invention.
Par risque cardiométabolique on entend un syndrome qui regroupe au moins 3 facteurs de risque comme le tour de taille, la glycémie et tension artérielle, le HDL cholestérol , le tabagisme et l'hérédité. Ce syndrome métabolique amène à plusieurs pathologies qui sont en particulier : le diabète de type II, l'athérosclérose, la coronaropathie ischémique, la démence cérébrovasculaire, l'accident vasculaire cérébral, l'artériopathie oblitérante des membres inférieurs , l'infertilité métabolique, les maladies hépatiques : stéatose, fibrose, cirrhose.  Cardiometabolic risk is defined as a syndrome that includes at least 3 risk factors such as waist circumference, blood glucose and blood pressure, HDL cholesterol, smoking and heredity. This metabolic syndrome leads to several pathologies that are in particular: type II diabetes, atherosclerosis, ischemic coronary artery disease, cerebrovascular dementia, stroke, arterial occlusive disease of the lower limbs, metabolic infertility, liver diseases: steatosis, fibrosis, cirrhosis.
Par hydrolysat de lactosérum au sens de l'invention on entend toute molécule ou mélange de molécules obtenu(e) à partir de lactosérum en particulier le lactosérum hydrolysé par un procédé comprenant une étape d'hydrolyse chimique ou d'hydrolyse enzymatique.  Whey hydrolyzate within the meaning of the invention is understood to mean any molecule or mixture of molecules obtained from whey, in particular whey hydrolysed by a process comprising a chemical hydrolysis or enzymatic hydrolysis step.
De façon particulièrement adaptée, il s'agit d'un hydrolysat peptidique. Il comprend préférentiellement au moins 75% de protéines ou de peptides, en poids de l'hydrolysat. L'hydrolysat de lactosérum a un poids moléculaire compris entre 200 et 5000 daltons. Préférentiellement au moins 55% du total des molécules de l'hydrolysat de lactosérum a un poids moléculaire inférieur ou égal à 1000 daltons.  In a particularly suitable way, it is a peptide hydrolyzate. It preferably comprises at least 75% of proteins or peptides, by weight of the hydrolyzate. The whey hydrolyzate has a molecular weight of between 200 and 5000 daltons. Preferably at least 55% of the total molecules of the whey hydrolyzate has a molecular weight less than or equal to 1000 daltons.
Il convient de favoriser la taille la plus petite possible des molécules car elle permet de désenclaver les biopeptides actifs du lactosérum qui sont prisonniers des macro peptides. Cette petite taille permet aux molécules de passer le tractus digestif rapidement, entre 15 et 30 minutes, de façon intacte sans être enveloppées dans une masse qui sera coupée par les enzymes digestives de façon aléatoire.  It is advisable to favor the smallest possible size of the molecules because it makes it possible to open up the active biopeptides of the whey which are prisoners of the macro peptides. This small size allows the molecules to pass the digestive tract quickly, between 15 and 30 minutes, intact without being wrapped in a mass that will be cut by the digestive enzymes at random.
L'hydrolysat de lactosérum est constitué essentiellement de petits peptides en particulier bi et tri-peptides.  The whey hydrolyzate consists essentially of small peptides, in particular bi and tri-peptides.
La taille des molécules dans l'hydrolysat peut être modulée par microfiltration.  The size of the molecules in the hydrolyzate can be modulated by microfiltration.
Très préférentiellement l'hydrolysat est obtenu avec une hydrolyse dont le taux est compris entre 15 et 35%. Le taux ne peut être supérieur, pour le moment, à 35% car au-dessus de 35% l'amertume est tellement prononcée qu'elle ne peut être maîtrisée et en outre la composition aurait plus d'acides aminés libres que de biopeptides actifs ce qui pourrait faire perdre de l'efficacité et la maîtrise du traitement. Very preferably, the hydrolyzate is obtained with a hydrolysis whose level is between 15 and 35%. The rate can not be higher, for the moment, at 35% because above 35% the bitterness is so pronounced that it can not be controlled and in addition the composition would have more free amino acids than active biopeptides which could cause loss of effectiveness and control of treatment.
L'alpha lactalbumine est un principe actif nutritionnel composant du lactosérum particulièrement riche en tryptophane et en acides aminés branchés.  Alpha lactalbumin is a nutritional active component of whey particularly rich in tryptophan and branched amino acids.
Le calcium de lait est un calcium extrait du lait et qui conserve une action thérapeutique supérieure au calcium synthétique en raison de la présence rémanente de petits peptides bioactifs. Milk calcium is a calcium extracted from milk and retains a therapeutic action superior to synthetic calcium due to the residual presence of small bioactive peptides.
Par régulateur des cycles AMPK et/ou MAPK et/ou PPAR a et γ et/ou SIRT1, on entend toute molécule ou mélange de molécules agissant sur au moins un des cycles AMPK et/ou MAPK et/ou PPAR a et y et/ou SIRT1. Il peut s'agir :  AMPK and / or MAPK and / or PPAR cycle regulator a and γ and / or SIRT1 means any molecule or mixture of molecules acting on at least one of the AMPK and / or MAPK and / or PPAR cycles a and y and / or or SIRT1. It could be :
d'un principe actif nutritionnel comme les tocophérols, la vitamine B6, la leucine ou les acides aminés branchés : la composition peut contenir un ou plusieurs tocophérol(s), ou de la vitamine B6, ou de la leucine, ou un ou plusieurs acide(s) aminé(s) branché(s), ou un mélange d'au moins deux de ces molécules  a nutritional active ingredient such as tocopherols, vitamin B6, leucine or branched amino acids: the composition may contain one or more tocopherol (s), or vitamin B6, or leucine, or one or more acid (s) amino (s) plugged (s), or a mixture of at least two of these molecules
- d'un principe actif pharmaceutique comme la metformine et les statines : la composition peut comprendre de la metformine, ou une ou plusieurs statines, ou un mélange de metformine et de statine(s).  a pharmaceutical active ingredient such as metformin and statins: the composition may comprise metformin, or one or more statins, or a mixture of metformin and statin (s).
Le régulateur des cycles AMPK et/ou MAPK et/ou PPAR a et y et/ou SIRT1 est préférentiellement un mimétique ou un agoniste des thiazolinediones. The regulator AMPK cycles and / or MAPK and / or PPAR and y and / or SIRT1 is preferably a mimetic or agonist thiazolinediones.
Par mimétique des thiazolinediones, on entend une molécule ou mélange de molécules qui copie intégralement le mode d'action des thiazolinediones en raison de sa structure chimique similaire, mais autant que possible sans en avoir les inconvénients. By thiazolinediones mimetic is meant a molecule or mixture of molecules that fully copies the mode of action of thiazolinediones because of its similar chemical structure, but as much as possible without the disadvantages.
Par agoniste des thiazolinediones, on entend une molécule ou mélange de molécules qui agit de la même manière que les thiazolinediones, mais autant que possible sans en avoir les inconvénients. By agonist thiazolinediones means a molecule or mixture of molecules which acts in the same way as the thiazolinediones, but as much as possible without the disadvantages.
Les thiazolinediones ont l'avantage d'agir notamment comme régulateur avec une action puissante des cycles PPARy et AMPK et indirectement sur SIRT1. Cette action mime une restriction calorique accompagnée d'une activité physique. Toutefois, les effets secondaires associés comme la prise de poids, les hépatites, la rétention hydrosoudée et l'augmentation du risque cardiaque par l'augmentation des cellules spumeuses, ont amené la suppression des autorisations de commercialisation des thiazolinediones dans de nombreux pays. Selon l'invention, le mimétique ou l'agoniste des thiazolinediones est choisi parmi la famille des tocophérols ou la vitamine B6 ou la leucine ou parmi la famille des acides aminés branchés. S'il s'agit du tocophérol, il doit s'agir préférentiellement d'un mélange de a et de γ tocophérol, encore plus préférentiellement dans des proportions de 75% pour le γ et de 25% pour l'a. Thiazolinediones have the advantage of acting in particular as a regulator with a powerful action of PPARy and AMPK cycles and indirectly on SIRT1. This action mimics a caloric restriction accompanied by a physical activity. However, associated side effects such as weight gain, hepatitis, fluid-tight retention and increased cardiac risk due to increased foam cells have led to the removal of marketing authorizations for thiazolinediones in many countries. According to the invention, the thiazolinediones mimetic or agonist is chosen from the family of tocopherols or vitamin B6 or leucine or from the family of branched amino acids. If it is tocopherol, it should preferably be a mixture of α and γ tocopherol, even more preferably in proportions of 75% for γ and 25% for α.
La composition selon l'invention peut contenir éventuellement un ou plusieurs principe(s) actif(s) pharmaceutique(s) activateur(s) des cycles AMPK et/ou MAPK et/ou PPAR a et γ et/ou SIRTl, choisis parmi la metformine et le statines, notamment la simvastatine en raison de sa maniabilité, mais également l'atorvastatine, la pravastatine, la rosuvastatine, la fluvastatine ou la lovastatine ou un mélange d'au moins deux de ces statines. La quantité de principe(s) actif(s) pharmaceutique(s) régulateur(s) des cycles AMPK et/ou MAPK et/ou PPAR a et Y et/ou SIRTl est de 200 à 700 mg pour la metformine et de 2.5 à 10 mg pour les statines, pour entre 20 et 40 g de composition sans excipients.  The composition according to the invention may optionally contain one or more active pharmaceutical ingredient (s) activator (s) AMPK cycles and / or MAPK and / or PPAR a and γ and / or SIRTl, chosen from the metformin and statins, including simvastatin because of its workability, but also atorvastatin, pravastatin, rosuvastatin, fluvastatin or lovastatin or a mixture of at least two of these statins. The amount of active pharmaceutical ingredient (s) regulator (s) AMPK cycles and / or MAPK and / or PPAR and Y and / or SIRTl is 200 to 700 mg for metformin and 2.5 to 10 mg for statins, for between 20 and 40 g of composition without excipients.
Les différents constituants de la composition agissent en synergie pour une action très efficace.  The different constituents of the composition act in synergy for a very effective action.
La composition selon l'invention est en particulier capable d'agir sur le niveau d'adiponectine.  The composition according to the invention is in particular capable of acting on the level of adiponectin.
L'adiponectine est une molécule produite en particulier par les adipocytes du tissu adipeux viscéral. Elle agit au niveau périphérique par deux récepteurs au travers desquels elle régule les cycles AMPK, MAPK, PPARa, PPARy, SIRTl et inhibe le signal N FKB.  Adiponectin is a molecule produced in particular by adipocytes of visceral adipose tissue. It acts at the peripheral level by two receivers through which it regulates the AMPK, MAPK, PPARa, PPARy, SIRT1 cycles and inhibits the N FKB signal.
Ces effets sont croisés puisque la sécrétion d'adiponectine est elle-même dépendante de plusieurs facteurs, dont AMPK, MAPK, PPAR et SIRTl : une déphosphorylation de ΓΑΜΡΚ, de MAPK, des PPAR et/ou de SIRTl entraîne une diminution de la sécrétion d'adiponectine. Le rôle de l'adiponectine est multiple, puisque notamment elle est capable de :  These effects are crossed since the secretion of adiponectin is itself dependent on several factors, including AMPK, MAPK, PPAR and SIRT1: a dephosphorylation of ΓΑΜΡΚ, MAPK, PPAR and / or SIRT1 leads to a decrease in the secretion of adiponectin. The role of adiponectin is multiple, since it is able to:
- supprimer les excès de ROS (espèces oxygénées réactives) et RNS (espèces nitrogénées réactives),  - to suppress the excess of ROS (reactive oxygen species) and RNS (reactive nitrogen species),
- augmenter l'oxyde nitrique NO à travers AMPK,  - increase nitric oxide NO through AMPK,
- diminuer l'expression de LPS (lipopolysaccharide) qui active les macrophages du tissu adipeux viscéral,  to reduce the expression of LPS (lipopolysaccharide) which activates the macrophages of the visceral adipose tissue,
- diminuer l'inflammation en particulier de TNFa par la modulation du signal N FKB, to reduce the inflammation, in particular of TNFa, by the modulation of the N FKB signal,
- pallier les conséquences de l'oxydation et réduire les effets de l'ischémie sur les tissus endommagés (en particulier dans l'infarctus du myocarde), - réguler la calcification des artères provoquée par la TNFa à travers AMPK, - mitigate the consequences of oxidation and reduce the effects of ischemia on damaged tissues (especially in myocardial infarction), - regulate the calcification of arteries caused by TNFa through AMPK,
- se corréler positivement avec le cholestérol HDL ( « High Density Lipoprotein » lipoprotéine de haute densité) mais négativement avec les triglycérides,  - to correlate positively with high density lipoprotein (HDL) cholesterol but negatively with triglycerides,
- réguler AMPK et MAPK et donc le ratio AMP/ ATP,  regulate AMPK and MAPK and therefore the AMP / ATP ratio,
- agir sur une diminution de la stéatose hépatique,  - to act on a decrease of the fatty liver,
- diminuer dans les vaisseaux l'adhésion plaquettaire et leur migration, et freiner la formation de cellules spumeuses,  - decrease platelet adhesion and migration in the vessels, and slow down the formation of foam cells,
- augmenter dans le muscle l'utilisation du glucose et la oxydation des acides gras, donc de prévenir l'état diabétique,  - to increase in the muscle the use of the glucose and the oxidation of the fatty acids, thus to prevent the diabetic state,
- diminuer dans le foie la glycogenèse et augmenter la oxydation des acides gras, - decrease in the liver glycogenesis and increase the oxidation of fatty acids,
- se lier directement avec le microbiote pour sa forme HMV (« High Molecular Weight » poids moléculaire élevé). - bind directly with the microbiota for its HMV (High Molecular Weight) form.
Or, le niveau d'adiponectine est très bas chez les personnes présentant un risque cardiométabolique, mais également chez les obèses en insulino résistance, les diabétiques, les personnes avec une lipodystrophie, les personnes avec une stéatose hépatique, NAFLD, NASH, les personnes en hypertension et les personnes avec une coronopathie. L'adiponectine est déficiente en particulier en raison de l'augmentation des adipocytokines inflammatoires, notamment TNFa, qui agissent négativement à travers la transcription, la translation et le turnover d'AMPK, de MAPK, des PPAR et de SIRTl, provoquant leur baisse par déphosphorylation et donc une diminution de la sécrétion d'adiponectine.  However, the level of adiponectin is very low in people with cardiometabolic risk, but also in obese insulin resistance, diabetics, people with lipodystrophy, people with fatty liver, NAFLD, NASH, people with hypertension and people with coronary artery disease. Adiponectin is deficient in particular because of the increase of inflammatory adipocytokines, in particular TNFα, which act negatively through the transcription, translation and turnover of AMPK, MAPK, PPAR and SIRT1, causing their decrease by dephosphorylation and therefore a decrease in the secretion of adiponectin.
La composition selon l'invention permet d'augmenter le taux d'adiponectine circulant et/ou de réguler sa sécrétion à long terme.  The composition according to the invention makes it possible to increase the rate of circulating adiponectin and / or to regulate its secretion in the long term.
En particulier, la présence d'au moins un régulateur des cycles AMPK et/ou MAPK et/ou PPAR a et y et/ou SIRTl, notamment un mimétique ou agoniste des thiazolinediones, permet d'activer AMPK et/ou MAPK et/ou PPAR a et γ et/ou SIRTl et donc d'augmenter le niveau d'adiponectine.  In particular, the presence of at least one regulator of the AMPK and / or MAPK and / or PPAR α and γ and / or SIRT1 cycles, in particular a thiazolinediones mimetic or agonist, makes it possible to activate AMPK and / or MAPK and / or PPAR has and γ and / or SIRT1 and therefore to increase the level of adiponectin.
Le calcium de lait permet également d'augmenter le taux d'adiponectine, en particulier d'adiponectine HMW.  Milk calcium also increases the level of adiponectin, especially adiponectin HMW.
Selon un autre aspect, la composition selon l'invention est capable d'agir sur le niveau de sérotonine.  In another aspect, the composition according to the invention is capable of acting on the level of serotonin.
La sérotonine est une hormone qui agit notamment sur l'humeur et la dépression, le stress, le sommeil, la prise alimentaire et le comportement alimentaire déviant comme les boulimies. Elle se trouve essentiellement dans l'intestin au niveau des cellules chromaffines, mais également dans les plaquettes et dans le cerveau. Serotonin is a hormone that acts in particular on mood and depression, stress, sleep, food intake and deviant eating behavior such as bulimia. It is mainly found in the intestine in the chromaffin cells, but also in the platelets and in the brain.
Le précurseur de la sérotonine est le tryptophane qui se transforme en 5HTP et ensuite en 5HT, la sérotonine. Ses métabolites sont le 5-HIAA (5-hydroxy-indol-acétique), le 5-HTOL (5- hydroxy-tryptophol) et ses dérivés le N-acétyl-5HT et la mélatonine.  The precursor of serotonin is tryptophan, which is transformed into 5HTP and then into 5HT, serotonin. Its metabolites are 5-HIAA (5-hydroxy-indol-acetic), 5-HTOL (5-hydroxy-tryptophol) and its derivatives N-acetyl-5HT and melatonin.
Seul le tryptophane circulant libre, qui ne représente que 1% du tryptophane, est capable de passer la barrière encéphalique. De plus, pour passer la barrière encéphalique, le tryptophane est en compétition avec les acides aminés branchés et aromatiques, c'est-à-dire les neutres, le seuil physiologique du rapport tryptophane sur ces acides aminés neutres étant de 6%. Au niveau du cerveau, l'hémi vie de la sérotonine est de quelques minutes. Il est donc nécessaire d'avoir une grande quantité de tryptophane plasmatique pour permettre un passage régulier de la barrière et assurer au cerveau la quantité nécessaire de sérotonine. Au niveau de l'intestin la sérotonine est abondante (80% de la production totale) et active la protéine GLP1 qui communique directement avec le cerveau pour enclencher la satiété. Il existe ainsi deux systèmes qui déterminent au niveau cérébral la satiété et le rassasiement.  Only free circulating tryptophan, which accounts for only 1% of tryptophan, is able to pass the encephalic barrier. In addition, to pass the brain barrier, tryptophan is in competition with the branched and aromatic amino acids, that is to say the neutrals, the physiological threshold of the tryptophan ratio on these neutral amino acids being 6%. In the brain, the hemi-life of serotonin is a few minutes. It is therefore necessary to have a large amount of plasma tryptophan to allow a smooth passage of the barrier and provide the brain with the necessary amount of serotonin. In the intestine serotonin is abundant (80% of total production) and activates the GLP1 protein that communicates directly with the brain to trigger satiety. There are two systems that determine satiety and satiety at the cerebral level.
Le syndrome métabolique et le surpoids abdominal entraînent une déficience en sérotonine. C'est l'inflammation des adipocytokines qui entraîne la dégradation de la sérotonine en 5HIAA au niveau du foie. En effet l'inflammation privilégie la voie kynurénique.  Metabolic syndrome and abdominal overweight result in serotonin deficiency. It is the inflammation of adipocytokines that leads to the breakdown of serotonin into 5HIAA in the liver. In fact, inflammation favors the kynurenic pathway.
La composition selon l'invention permet d'augmenter le taux de sérotonine en particulier grâce au tryptophane apporté notamment par l'hydrolysat de lactosérum et l'alpha lactalbumine, mais aussi par la baisse de l'inflammation. Le tryptophane doit préférentiellement représenter entre 6 et 9%, encore plus préférentiellement environ 7% en poids des acides aminés neutres présents dans la composition. Cette proportion particulière permet d'assurer qu'une quantité adaptée de tryptophane puisse traverser la barrière encéphalique pour être transformée en sérotonine. L'apport journalier de tryptophane par la composition selon l'invention est préférentiellement, pour les personnes en syndrome métabolique ou en stade de pré diabète, d'au moins 0,5g, préférentiellement de 0.5 à 0,8 g. Cette augmentation du taux de sérotonine, en plus de son effet direct notamment sur la sensation de satiété, joue également en faveur d'une augmentation du taux d'adiponectine. En effet, les métabolites de la sérotonine agissent comme des agonistes de PPARy et donc stimulent la sécrétion d'adiponectine. Par ailleurs, des résultats d'essais menés avec l'hydrolysat de lactosérum selon l'invention sur le tissu adipeux blanc, ont montré que le cycle de l'énergie était activé par la consommation accrue d'oxygène de 63% et que la lipolyse des adipocytes était accéléré par la libération du glycérol (20%) et enfin que la transformation des pré adipocytes en adipocytes était freinée par la modulation de MCP1. The composition according to the invention makes it possible to increase the level of serotonin, in particular thanks to the tryptophan provided in particular by the whey hydrolyzate and the alpha lactalbumin, but also by the reduction of the inflammation. Tryptophan should preferably represent between 6 and 9%, more preferably approximately 7% by weight of the neutral amino acids present in the composition. This particular proportion ensures that an appropriate amount of tryptophan can cross the brain barrier to be converted to serotonin. The daily tryptophan intake by the composition according to the invention is preferably, for people with metabolic syndrome or pre-diabetes stage, at least 0.5 g, preferably from 0.5 to 0.8 g. This increase in serotonin levels, in addition to its direct effect on the feeling of satiety, also favors an increase in adiponectin levels. In fact, serotonin metabolites act as PPARγ agonists and therefore stimulate the secretion of adiponectin. Moreover, results of tests conducted with the whey hydrolyzate according to the invention on white adipose tissue, have shown that the energy cycle was activated by the increased consumption of oxygen by 63% and that lipolysis adipocytes were accelerated by the release of glycerol (20%) and finally that the transformation of pre adipocytes into adipocytes was slowed by the modulation of MCP1.
Enfin, la composition selon l'invention permet d'apporter une quantité importante d'acides aminés de qualité, en particulier de leucine et d'isoleucine, en plus du tryptophane déjà mentionné.  Finally, the composition according to the invention makes it possible to supply a large quantity of high quality amino acids, in particular leucine and isoleucine, in addition to the tryptophan already mentioned.
La leucine est notamment capable d'agir sur SIRT1, AMPK et PPARy et permet donc une augmentation de l'adiponectine. De plus, l'hydroxybutirate, métabolite actif de la leucine, régule la β-oxydation des lipides à travers AMPK et SIRT1. Selon l'invention la leucine peut provenir de l'hydrolysat de lactosérum et de l'alpha lactalbumine, et elle peut aussi être utilisée seule, comme régulateur des cycles AMPK et/ou MAPK et/ou PPAR a et γ et/ou SIRT1.  Leucine is particularly capable of acting on SIRT1, AMPK and PPARy and therefore allows an increase in adiponectin. In addition, hydroxybutirate, the active metabolite of leucine, regulates the β-oxidation of lipids through AMPK and SIRT1. According to the invention the leucine can come from whey hydrolyzate and alpha lactalbumin, and it can also be used alone, as a regulator of AMPK cycles and / or MAPK and / or PPAR a and γ and / or SIRT1.
L'isoleucine quant à elle induit une baisse de la glycémie en augmentant l'utilisation de glucose à travers AMPK notamment. Isoleucine induces a decrease in blood glucose by increasing the use of glucose through AMPK in particular.
Dans la composition, le rapport du poids de leucine/acides aminés totaux de la composition est préférentiellement compris entre 10 et 15%, le rapport en poids de leucine/acides aminés neutres de la composition est préférentiellement compris entre 30 et 40%, et le rapport en poids de leucine/acides branchés de la composition est préférentiellement compris entre 45 et 55%. L'apport journalier de leucine par la composition selon l'invention est préférentiellement d'au moins 5g.  In the composition, the ratio of the weight of leucine / total amino acids of the composition is preferably between 10 and 15%, the weight ratio of leucine / neutral amino acids of the composition is preferably between 30 and 40%, and the ratio by weight of leucine / branched acids of the composition is preferably between 45 and 55%. The daily intake of leucine by the composition according to the invention is preferably at least 5 g.
Par ailleurs, dans la composition, le rapport en poids d'isoleucine/acides aminés totaux de la composition est préférentiellement compris entre 5 et 10%, le rapport en poids d'isoleucine/acides aminés neutres de la composition est préférentiellement compris entre 15 et 25%, et le rapport en poids d'isoleucine/acides branchés de la composition est préférentiellement compris entre 20 et 30%. L'apport journalier d'isoleucine par la composition selon l'invention est préférentiellement d'au moins 2,5 g.  Moreover, in the composition, the ratio by weight of isoleucine / total amino acids of the composition is preferably between 5 and 10%, the ratio by weight of isoleucine / neutral amino acids of the composition is preferably between 15 and 25%, and the ratio by weight of isoleucine / branched acids of the composition is preferably between 20 and 30%. The daily intake of isoleucine by the composition according to the invention is preferably at least 2.5 g.
Le tryptophane, la leucine et l'isoleucine sont contenus dans l'hydrolysat de lactosérum particulier utilisé et dans l'alpha lactalbumine. Le choix de ces deux composés est essentiel pour l'effet de la composition. Tout d'abord, selon l'invention, les protéines laitières de lactosérum sont plus adaptées que les protéines végétales qui possèdent moins d'acides aminés branchés ou que les acides aminés de fermentation de biotechnologie qui ont une activité inférieure à celle des acides aminés de lactosérum en raison de l'absence des biopeptides actifs. De même la forme du lactosérum est importante ca r la digestibilité et donc la disponibilité des acides aminés est différente et joue sur la chronobiologie de la prise selon que l'on utilise du concentrât, de l'isolât ou de l'hydrolysat. Les meilleurs effets pour répondre à l'objectif de l'invention sont obtenus avec un hydrolysat contenant des petites molécules, en particulier des bi et tri peptides qui mettent en exergue les biopeptides du lactosérum. Les molécules de l'hydrolysat doivent avoir une taille comprise entre 200 et 5000 daltons qui représentent l'optimum de présence de biopeptides de lactosérum qui sont désenclavés des macro peptides. Pour une efficacité encore optimisée au moins 55% du total des molécules de l'hydrolysat de lactosérum a un poids moléculaire inférieur ou égal à 1000 daltons ce qui correspond à un peptide de 6 acides aminés maximum. Pour obtenir des molécules aussi petites, il est nécessaire d'avoir recours à une hydrolyse du lactosérum avec une degré d'hydrolyse compris entre 15% et 35%. Tryptophan, leucine and isoleucine are contained in the particular whey hydrolyzate used and in alpha lactalbumin. The choice of these two compounds is essential for the effect of the composition. First, according to the invention, dairy whey proteins are more suitable than plant proteins which have fewer branched amino acids or the fermentation amino acids of biotechnology which have a lower activity than the amino acids of whey because of the absence of active biopeptides. Similarly, the shape of the whey is important that digestibility and therefore the availability of amino acids is different and plays on the chronobiology of the intake according to whether one uses concentrate, isolate or hydrolyzate. The best effects to meet the objective of the invention are obtained with a hydrolyzate containing small molecules, in particular bi and tri peptides which highlight whey biopeptides. The molecules of the hydrolyzate must have a size of between 200 and 5000 daltons which represent the optimum presence of whey biopeptides which are disengaged from the macro peptides. For still optimized efficiency at least 55% of the total molecules of the whey hydrolyzate has a molecular weight less than or equal to 1000 daltons which corresponds to a peptide of 6 amino acids maximum. To obtain such small molecules, it is necessary to resort to hydrolysis of the whey with a degree of hydrolysis of between 15% and 35%.
La présence d'alpha lactalbumine est nécessaire dans la composition selon l'invention, car l'utilisation d'un hydrolysat de lactosérum seul, même d'excellente qualité, ne suffit pas à apporter les proportions et les quantités nécessaires en certains acides aminés, en particulier en tryptophane, leucine et isoleucine. De plus l'alpha lactalbumine, comme le calcium de lait, permettent d'atténuer l'amertume du lactosérum, en particulier dans le cas d'une hydrolyse avec un taux compris entre 15% et 35% qui augmente cette amertume. L'alpha lactalbumine est, très préférentiellement, présente en une proportion inférieure ou égale à 50% en poids par rapport au lactosérum. Le ratio en poids de protéines entre l'alpha lactalbumine et l'hydrolysat est compris entre 50/50 et 30/70.  The presence of alpha lactalbumin is necessary in the composition according to the invention, because the use of a whey hydrolyzate alone, even of excellent quality, is not sufficient to provide the necessary proportions and amounts of certain amino acids, especially tryptophan, leucine and isoleucine. In addition, alpha lactalbumin, like milk calcium, can reduce the bitterness of whey, especially in the case of hydrolysis with a rate of between 15% and 35% which increases this bitterness. The alpha lactalbumin is, very preferably, present in a proportion less than or equal to 50% by weight relative to whey. The ratio by weight of protein between alpha lactalbumin and the hydrolyzate is between 50/50 and 30/70.
Le mélange hydrolysat de lactosérum et d'alpha lactalbumine de la composition selon l'invention doit donc préférentiellement contenir au moins du tryptophane, de la leucine et de l'isoleucine. Encore plus préférentiellement il contient également de la glutamine et de l'arginine.  The hydrolyzate mixture of lactoserum and alpha lactalbumin of the composition according to the invention should therefore preferably contain at least tryptophan, leucine and isoleucine. Even more preferentially it also contains glutamine and arginine.
La présence de glutamine ou d'acide glutamique permet de réduire l'hyperperméabilité de la barrière intestinale. L'hyperperméabilité de la barrière intestinale, à travers le passage des LPS, est impliquée dans l'activation du signal N FKB et donc dans la baisse de l'adiponectine et surtout l'augmentation des adipocytokines inflammatoires comme IL6 et TNFa. L'action de la glutamine ou de l'acide glutamique est renforcée par la présence de leucine et d'arginine. Préférentiellement la glutamine et/ou l'acide glutamique représentent plus de 150% du poids de la leucine présente dans la composition. De même si l'arginine est également présente, la glutamine et/ou l'acide glutamique représentent préférentiellement en poids au moins 7 fois l'arginine. The presence of glutamine or glutamic acid reduces the hyperpermeability of the intestinal barrier. The hyperpermeability of the intestinal barrier, through the passage of LPS, is involved in the activation of the N FKB signal and thus in the decrease of adiponectin and especially the increase of inflammatory adipocytokines like IL6 and TNFa. The action of glutamine or glutamic acid is enhanced by the presence of leucine and arginine. Preferentially, glutamine and / or glutamic acid represent more than 150% of the weight of the leucine present in the composition. Similarly, if arginine is also present, glutamine and / or glutamic acid preferably represent by weight at least 7 times arginine.
La composition peut également contenir d'autres acides aminés comme la valine, la phénylalanine ou la tyrosine notamment.  The composition may also contain other amino acids such as valine, phenylalanine or tyrosine in particular.
En plus du mélange d'hydrolysat, d'alpha lactalbumine, d'un ou plusieurs régulateur(s) des cycles AMPK et/ou MAPK et/ou PPAR a et γ et/ou SIRT1 et du calcium de lait, le mélange de principes actifs de la composition selon l'invention peut comprendre un ou plusieurs éléments ajoutés librement choisis notamment parmi la vitamine B9 et la vitamine D.  In addition to the mixture of hydrolyzate, alpha lactalbumin, one or more AMPK and / or MAPK and / or PPAR and / or SIRT1 and / or milk calcium regulator (s), the mixture of principles active ingredients of the composition according to the invention may comprise one or more elements added freely chosen in particular from vitamin B9 and vitamin D.
De même, la composition peut contenir des acides gras essentiels, notamment des omégas 3. Préférentiellement, il s'agit d'omégas 3 d'origine végétale ALA (acide alpha-linolénique), avec une proportion élevée d'EPA (acide eicosapentaénoïque) ou encore directement d'EPA purifié. Likewise, the composition may contain essential fatty acids, in particular omega 3s. Preferably, it is omega 3 of plant origin ALA (alpha-linolenic acid), with a high proportion of EPA (eicosapentaenoic acid). or directly from purified EPA.
La présence éventuelle de metformine a l'avantage d'agir à travers AMPK pour inhiber la glycogenèse hépatique, et améliore le dysfonctionnement endothélial, mais elle est associée à de nombreux effets secondaires qui perturbent le traitement, comme des nausées et des vomissements et dans le pire des cas une acidose lactique. Ces intolérances peuvent être provoquées notamment par une insuffisance rénale mais aussi par la mutation du gène transporteur OCT1 qui provoque une saturation de metformine avec des concentrations de 30 ± 19 ng/ml alors que les doses journalières du médicament étaient normales de 1 à 3g/jour. La présence des autres constituants de la composition selon l'invention permet de pouvoir baisser les doses d'activateur des cycles AMPK et/ou MAPK et/ou PPAR a et γ et/ou SIRT1, en particulier de metformine tout en conservant la même activité mais sans effets secondaires. La dose journalière de metformine dans la composition selon l'invention est inférieure ou égale à lg, préférentiellement comprise entre 500 mg et lg.  The potential presence of metformin has the advantage of acting through AMPK to inhibit hepatic glycogenesis, and improves endothelial dysfunction, but is associated with many side effects that disrupt treatment such as nausea and vomiting and in the worst case lactic acidosis. These intolerances can be caused in particular by a renal insufficiency but also by the mutation of the transporter gene OCT1 which causes a saturation of metformin with concentrations of 30 ± 19 ng / ml whereas the daily doses of the drug were normal of 1 to 3g / day . The presence of the other constituents of the composition according to the invention makes it possible to be able to lower the activator doses of the AMPK and / or MAPK and / or PPAR α and γ and / or SIRT1 cycles, in particular of metformin while retaining the same activity. but without side effects. The daily dose of metformin in the composition according to the invention is less than or equal to 1 g, preferably between 500 mg and 1 g.
Selon une variante, la composition peut aussi contenir des constituants supplémentaires connus pour améliorer l'adaptation des cycles AMPK, MAPK, PPAR et SIRT1 tels que le zinc, le chrome, la curcumine, le SOD, la catalase, le glutathion, le resvératrol et/ou des anthocyanes. La curcumine, à faible dose pour ne pas atteindre son seuil pro-oxydant, permet de réduire l'hyperperméabilité de la barrière intestinale comme la glutamine. Le SOD, la catalase et le glutathion, par leur puissant rôle antioxydant, s'attaque aux ROS et module indirectement le signal N FKB de l'inflammation et participent donc à une augmentation de la sécrétion d'adiponectine. Le SOD agit également sur la prévention de la β-oxydation du LDL. Le resvératrol, les anthocyanes et la curcumine agissent au niveau de PPAR et AM PK. According to one variant, the composition may also contain additional constituents known to improve the adaptation of the AMPK, MAPK, PPAR and SIRT1 cycles such as zinc, chromium, curcumin, SOD, catalase, glutathione, resveratrol and or anthocyanins. Curcumin, at a low dose so as not to reach its pro-oxidant threshold, reduces the hyperpermeability of the intestinal barrier such as glutamine. SOD, catalase and glutathione, by their powerful antioxidant role, attack the ROS and indirectly modulate the N FKB signal of inflammation and therefore participate in an increase in the secretion of adiponectin. SOD also acts on the prevention of β-oxidation of LDL. Resveratrol, anthocyanins and curcumin act at the level of PPAR and AM PK.
Les différents constituants de la composition selon l'invention agissent en synergie pour procurer des effets surprenants particulièrement adaptés à la prévention du risque cardiométabolique et de la stéatose hépatique et au traitement de l'état de pré diabète. Selon un mode de réalisation préféré, le mélange de principes actifs de la composition selon l'invention comprend au moins :  The various constituents of the composition according to the invention act in synergy to provide surprising effects particularly adapted to the prevention of cardiometabolic risk and hepatic steatosis and to the treatment of the state of pre-diabetes. According to a preferred embodiment, the mixture of active ingredients of the composition according to the invention comprises at least:
- entre 40 et 60% d'hydrolysat de lactosérum de poids moléculaire compris entre 200 et 5000 daltons,  between 40 and 60% of whey hydrolyzate with a molecular weight of between 200 and 5000 daltons,
- entre 38 et 55% d'alpha lactalbumine,  between 38 and 55% of alpha lactalbumin,
- entre 5 et 30 mg, préférentiellement entre 5 et 15 mg, d'au moins un régulateur nutritionnel des cycles AM PK et/ou MAPK et/ou PPAR a et γ et/ou SI RT1 choisi parmi la famille des tocophérols, la vitamine B6, la leucine, la famille des acides aminés branchés, pour entre 25 et 40 g de composition sans excipients,  between 5 and 30 mg, preferably between 5 and 15 mg, of at least one nutritional regulator of the AM PK and / or MAPK and / or PPAR α and γ and / or SI RT1 cycles chosen from the tocopherol family, vitamin B6, leucine, the family of branched amino acids, for between 25 and 40 g of composition without excipients,
- éventuellement un ou plusieurs principe(s) actif(s) pharmaceutique(s) régulateur(s) des cycles AM PK et/ou MAPK et/ou PPAR a et γ et/ou SI RT1 choisi(s) parmi la metformine et les statines,  optionally one or more pharmaceutical active ingredient (s) regulating the AM PK and / or MAPK and / or PPAR α and γ and / or SI RT1 cycles chosen from metformin and statins,
- entre 1 et 3% de calcium de lait.  - Between 1 and 3% milk calcium.
les pourcentages étant donnés en poids de matière sèche de la totalité des principes actifs présents de la composition (en dehors des éventuels excipients). the percentages being given by weight of dry matter of all the present active ingredients of the composition (apart from any excipients).
La composition peut également contenir des éléments ajoutés librement, tels que des vitamines et des minéraux, qui viennent s'ajouter aux constituants natifs de l'hydrolysat, de l'alpha lactalbumine, du ou des régulateurs des cycles AM PK et/ou MAPK et/ou PPAR a et γ et/ou SI RT1.  The composition may also contain freely added elements, such as vitamins and minerals, in addition to the native components of the hydrolyzate, alpha lactalbumin, or the regulators of the AM PK and / or MAPK cycles and / or PPAR a and γ and / or SI RT1.
La composition selon l'invention est préférentiellement constituée par au moins : The composition according to the invention is preferably constituted by at least:
1 à 3% de tryptophane,  1 to 3% tryptophan,
12 à 20 % d'acides aminés branchés, 6 à 10 % d'acides aminés aromatiques, 12 to 20% of branched amino acids, 6 to 10% aromatic amino acids,
10 et 20% de glutamine ou d'acide glutamique,  10 and 20% of glutamine or glutamic acid,
1,6 à 3% d'arginine,  1.6 to 3% arginine,
1,2 à 3% de calcium de lait,  1.2 to 3% milk calcium,
- 0,2 à l% d'EPA,  0.2 to 1% EPA,
1 à 2 mg de vitamine B6 pour 30g de composition sans excipients,  1 to 2 mg of vitamin B6 for 30 g of composition without excipients,
1 à 3 μg de vitamine D pour 30g de composition sans excipients,  1 to 3 μg of vitamin D for 30 g of composition without excipients,
75 à 150 μg de vitamine B9 pour 30g de composition sans excipients, 5 à 15 mg de vitamine E pour 30g de composition sans excipients.  75 to 150 μg of vitamin B9 for 30 g of composition without excipients, 5 to 15 mg of vitamin E for 30 g of composition without excipients.
les pourcentages étant donnés en poids de matière sèche de la totalité des principes actifs présents de la composition (en dehors des éventuels excipients), une partie des constituants provenant de l'hydrolysat, de l'alpha lactalbumine, du ou des régulateurs des cycles AMPK et/ou MAPK et/ou PPAR a et γ et/ou SIRTl et du calcium de lait et le reste étant ajouté librement sous forme de vitamines, minéraux et acides gras. the percentages being given, by weight of dry matter, of all the active ingredients present in the composition (apart from any excipients), a part of the constituents originating from the hydrolyzate, alpha lactalbumin or AMPK cycle regulator (s). and / or MAPK and / or PPAR a and γ and / or SIRT1 and milk calcium and the remainder being freely added in the form of vitamins, minerals and fatty acids.
Selon un autre mode de réalisation préféré, le mélange de principes actifs de la composition selon l'invention comprend au moins : According to another preferred embodiment, the mixture of active ingredients of the composition according to the invention comprises at least:
- entre 40 et 60% d'hydrolysat de lactosérum de poids moléculaire compris entre 200 et 5000 daltons,  between 40 and 60% of whey hydrolyzate with a molecular weight of between 200 and 5000 daltons,
- entre 38 et 55% d'alpha lactalbumine,  between 38 and 55% of alpha lactalbumin,
- entre 250 et 500 mg de principe(s) actif(s) pharmaceutique(s) activateur(s) des cycles AMPK et/ou MAPK et/ou PPAR a et γ et/ou SIRTl choisis parmi la metformine et les statines, pour entre 20 et 40 g de composition de composition sans excipients, et  between 250 and 500 mg of activating pharmaceutical ingredient (s) activator (s) AMPK cycles and / or MAPK and / or PPAR α and γ and / or SIRT1 selected from metformin and statins, for between 20 and 40 g of composition composition without excipients, and
- entre 5 et 30mg, préférentiellement entre 5 et 15mg, d'au moins un régulateur nutritionnel des cycles AMPK et/ou MAPK et/ou PPAR a et γ et/ou between 5 and 30 mg, preferably between 5 and 15 mg, of at least one nutritional regulator of the AMPK and / or MAPK cycles and / or PPAR α and γ and / or
SIRTl choisi parmi la famille des tocophérols, la vitamine B6, la leucine, la famille des acides aminés branchés, pour entre 20 et 40 g de composition de composition sans excipients, et SIRT1 chosen from the family of tocopherols, vitamin B6, leucine, the family of branched amino acids, for between 20 and 40 g of composition composition without excipients, and
- entre 1 et 3% de calcium de lait,  between 1 and 3% milk calcium,
les pourcentages étant donnés en poids de matière sèche de la totalité des principes actifs présents de la composition (en dehors des éventuels excipients). La composition peut également contenir des éléments ajoutés librement, tels que des vitamines et des minéraux, qui viennent s'ajouter aux constituants natifs de l'hydrolysat, de l'alpha lactalbumine, du ou des régulateurs des cycles AMPK et/ou MAPK et/ou PPAR a et γ et/ou SIRTl. the percentages being given by weight of dry matter of all the present active ingredients of the composition (apart from any excipients). The composition may also contain freely added elements, such as vitamins and minerals, in addition to the native components of the hydrolyzate, alpha lactalbumin, AMPK and / or MAPK cycle regulator (s) and / or or PPAR a and γ and / or SIRT1.
La composition selon l'invention peut être constituée par au moins : The composition according to the invention may consist of at least:
1 à 3% de tryptophane,  1 to 3% tryptophan,
12 à 20 % d'acides aminés branchés,  12 to 20% of branched amino acids,
6 à 10 % d'acides aminés aromatiques,  6 to 10% aromatic amino acids,
10 et 20% de glutamine ou d'acide glutamique,  10 and 20% of glutamine or glutamic acid,
- 1,6 à 3% d'arginine,  - 1.6 to 3% arginine,
1,2 à 3% de calcium de lait,  1.2 to 3% milk calcium,
- 0,2 à l% d'EPA,  0.2 to 1% EPA,
0,8 à 2% de metformine,  0.8 to 2% metformin,
1 à 2 mg de vitamine B6 pour 30g de composition sans excipients,  1 to 2 mg of vitamin B6 for 30 g of composition without excipients,
- 1 à 3 μg de vitamine D pour 30g de composition sans excipients, 1 to 3 μg of vitamin D for 30 g of composition without excipients,
75 à 150 μg de vitamine B9 pour 30g de composition sans excipients, 5 à 15 mg de vitamine E pour 30g de composition sans excipients, les pourcentages étant donnés en poids de matière sèche de la totalité des principes actifs présents de la composition (en dehors des éventuels excipients), une partie des constituants provenant de l'hydrolysat, de l'alpha lactalbumine, du ou des activateurs des cycles AMPK et/ou MAPK et/ou PPAR a et γ et/ou SIRTl, du ou des régulateurs des cycles AMPK et/ou MAPK et/ou PPAR a et γ et/ou SIRTl et du calcium de lait et le reste étant ajouté librement sous forme de vitamines et minéraux et acides gras. 75 to 150 μg of vitamin B9 per 30 g of composition without excipients, 5 to 15 mg of vitamin E per 30 g of composition without excipients, the percentages being given by weight of dry matter of all the active ingredients present in the composition (outside possible excipients), a part of the constituents originating from the hydrolyzate, alpha lactalbumin, activator (s) of the AMPK and / or MAPK and / or PPAR α and γ and / or SIRT1 cycles, of the cyclic regulator (s). AMPK and / or MAPK and / or PPAR α and γ and / or SIRT1 and milk calcium and the remainder being freely added in the form of vitamins and minerals and fatty acids.
Les acides aminés branchés des variantes de compositions ci-dessus sont constitués de leucine, d'isoleucine et de valine, préférentiellement de :  The branched amino acids of the above variant compositions consist of leucine, isoleucine and valine, preferentially:
- 7 à 10% de leucine,  7 to 10% leucine,
- 4 à 8% d'isoleucine, et  4 to 8% of isoleucine, and
- 3 à 6% de valine,  3-6% valine,
et les acides aminés aromatiques de tryptophane, de phénylalanine et de tyrosine, préférentiellement de : and the aromatic amino acids of tryptophan, phenylalanine and tyrosine, preferentially:
- 1 à 3% de tryptophane,  - 1 to 3% of tryptophan,
- de 2 à 6% de phénylalanine, et - de 2 à 4% de tyrosine. 2-6% phenylalanine, and from 2 to 4% of tyrosine.
La composition selon l'invention peut être obtenue par un procédé tel que décrit en suivant :  The composition according to the invention can be obtained by a process as described below:
- obtention d'un premier mélange par mélange des constituants dans l'ordre suivant : hydrolysat de lactosérum, alpha lactalbumine et calcium de lait ; le pH doit être aux alentours de 7 et stabilisé à ce niveau,  obtaining a first mixture by mixing the constituents in the following order: whey hydrolyzate, alpha lactalbumin and milk calcium; the pH should be around 7 and stabilized at this level,
- ajout au premier mélange du ou des régulateurs des cycles AMPK et/ou MAPK et/ou PPAR a et y et/ou SIRTl (régulateur(s) nutritionnel(s) et éventuellement principe(s) actif(s) pharmaceutique(s) régulateur(s)), et éventuellement des vitamines, minéraux et acides gras supplémentaires.  - addition to the first mixture of the AMPK and / or MAPK and / or PPAR cycle regulator (s) and y and / or SIRT1 (nutritional regulator (s) and optionally pharmaceutical active principle (s) regulator (s)), and possibly additional vitamins, minerals and fatty acids.
La composition peut être additionnée d'excipients et charges classiques connues de l'homme du métier. The composition may be supplemented with conventional excipients and fillers known to those skilled in the art.
On obtient ainsi une poudre qui peut être transformée en comprimé ou liquide, ou bien utilisée dans sa forme poudre en sachets, sticks, bidons ou gélules par exemple. Préférentiellement, elle se présente sous forme de poudre ou granules conditionnée dans un sachet à diluer dans l'eau. Elle peut aussi se présenter sous forme de boisson prête à l'emploi, de barres alimentaires ou extrudés.  A powder is thus obtained which can be converted into a tablet or liquid, or used in its powder form in sachets, sticks, cans or capsules, for example. Preferably, it is in the form of powder or granules packaged in a bag to be diluted in water. It can also be in the form of ready-to-use beverage, food bars or extruded bars.
La composition selon l'invention, lorsqu'elle est administrée par voie orale en quantité suffisante, permet en particulier :  The composition according to the invention, when it is administered orally in sufficient quantity, allows in particular:
de prévenir le risque cardiométabolique  to prevent cardiometabolic risk
- de prévenir la stéatose hépatique  - prevent hepatic steatosis
de traiter et/ou prévenir le pré diabète ou le diabète, de traiter et/ou prévenir les maladies cardiométaboliques de traiter et/ou prévenir l'infertilité et/ou la sous-fertilité des hommes et femmes en surpoids.  to treat and / or prevent pre diabetes or diabetes, to treat and / or prevent cardiometabolic diseases from treating and / or preventing the infertility and / or under-fertility of overweight men and women.
Les différents constituants de la composition selon l'invention permettent notamment d'augmenter la sécrétion d'adiponectine et de sérotonine, de diminuer les adipocytokines inflammatoires et l'insulinorésistance pour une action sur la perte du gras viscéral, du gras hépatique et du gras sous-cutané profond. The various constituents of the composition according to the invention make it possible in particular to increase the secretion of adiponectin and serotonin, to reduce inflammatory adipocytokines and insulin resistance for an action on the loss of visceral fat, liver fat and fat under -cutaneous deep.
Avantageusement elle agit comme coupe-faim et procure une sensation de satiété grâce à l'augmentation du taux de sérotonine, et par l'action des acides aminés branchés et du calcium de lait. La composition selon l'invention permet également de perdre durablement du gras viscéral en particulier grâce : Advantageously, it acts as an appetite suppressant and provides a feeling of satiety thanks to the increase of the rate of serotonin, and by the action of branched amino acids and milk calcium. The composition according to the invention also makes it possible to lose visceral fat for a long time, in particular by:
- à l'augmentation du taux de sérotonine notamment par l'apport de tryptophane, qui régule la satiété, directement au niveau cérébral ou indirectement dans l'intestin par la modulation de la sécrétion de GLP1 et CCK .  - the increase in serotonin levels in particular by the intake of tryptophan, which regulates satiety, directly at the cerebral level or indirectly in the intestine by modulating the secretion of GLP1 and CCK.
- à l'augmentation du taux d'adiponectine  - to increase the adiponectin level
- à la diminution l'inflammation par une régulation du signal N FKB des macrophages. De plus, elle peut diminuer le tour de taille, tout en maintenant la masse maigre notamment par l'apport d'acides aminés branchés.  - At the decrease of the inflammation by a regulation of the signal N FKB of the macrophages. In addition, it can reduce waist circumference, while maintaining lean mass including the supply of branched amino acids.
La composition selon l'invention est également capable d'agir sur de nombreux autres facteurs du risque cardiométabolique. En particulier, elle est capable de réduire le stress, de normaliser la tension artérielle, de diminuer l'inflammation IL6 , TNFa, PAI-1 et CRP ultrasensible, de limiter la coagulation (fibrinogène), de réguler le cholestérol et les triglycérides, de diminuer la glycémie et la glycémie post prandiale, l'insulinémie et d'une manière plus générale de réguler les cycles de l'énergie de la cellule par la régulation du ratio APM/TP à travers les cycles AMPK, MAPK, PPAR a et γ et SIRT1. The composition according to the invention is also capable of acting on many other factors of cardiometabolic risk. In particular, it is able to reduce stress, normalize blood pressure, reduce IL6 inflammation, TNFa, PAI-1 and CRP ultrasensitive, limit clotting (fibrinogen), regulate cholesterol and triglycerides, to reduce blood glucose and postprandial glucose, insulinemia and, more generally, to regulate cell energy cycles by regulating the APM / TP ratio through the AMPK, MAPK, PPAR a and γ cycles and SIRT1.
L'invention vise donc la composition telle que décrite précédemment pour son application comme produit de santé, en particulier comme médicament ou comme produit de nutrition médicale à administration orale pour la prévention du risque cardiométabolique et/ou pour la prévention de la stéatose hépatique et/ou pour la prévention et/ou le traitement de l'état de pré diabète de type II (et lutter ainsi contre l'apparition de diabète de type II), du diabète de type II, de maladies cardiométaboliques et/ou de l'infertilité et/ou la sous-fertilité chez l'être humain.  The invention therefore relates to the composition as described above for its application as a health product, in particular as a medicament or as an oral medical nutrition product for the prevention of cardiometabolic risk and / or for the prevention of hepatic steatosis and / or for the prevention and / or treatment of the state of type II pre-diabetes (and thus fight against the onset of type II diabetes), type II diabetes, cardiometabolic diseases and / or infertility and / or sub-fertility in humans.
En particulier, la composition selon l'invention peut être utilisée comme produit de santé pour diminuer la graisse viscérale et le gras sous-cutané profond chez les personnes en surcharge pondérale.  In particular, the composition according to the invention can be used as a health product to reduce visceral fat and deep subcutaneous fat in people overweight.
Le produit de santé peut spécifiquement être utilisé pour diminuer la graisse viscérale et le gras sous-cutané profond chez les personnes en surcharge pondérale et/ou pour diminuer le tour de taille et/ou réduire le stress et/ou normaliser la tension artérielle et/ou limiter l'oxydation et/ou diminuer l'inflammation CRP ultrasensible et/ou limiter la coagulation et/ou réguler le cholestérol et les triglycérides et/ou diminuer la glycémie et la glycémie post prandiale et/ou l'insulinémie et/ou diminuer l'hypersensibilité de la barrière intestinale et/ou rééquilibrer la flore intestinale et/ou lutter contre le diabète de type II. The health product can specifically be used to decrease visceral fat and deep subcutaneous fat in overweight and / or to reduce waist circumference and / or reduce stress and / or normalize blood pressure and / or or to limit the oxidation and / or decrease the ultrasensitive CRP inflammation and / or to limit coagulation and / or to regulate cholesterol and triglycerides and / or to lower blood glucose and blood sugar post prandial and / or insulinemia and / or decrease hypersensitivity of the intestinal barrier and / or rebalance the intestinal flora and / or fight against type II diabetes.
La dose journalière de composition selon l'invention (dose de mélange de principes actifs sans les excipients) est préférentiellement comprise entre 40 et 80 g, encore plus préférentiellement en deux prises comprises entre 20 et 40 g réparties un moment (généralement 1 heure) avant le déjeuner et l'autre avant le dîner. The daily dose of composition according to the invention (dose of mixture of active ingredients without excipients) is preferably between 40 and 80 g, more preferably in two doses of between 20 and 40 g distributed a time (usually 1 hour) before lunch and the other before dinner.
Avantageusement, la biodisponibilité dans l'organisme des acides aminés, peptides et protéines présents dans la composition est comprise entre 10 et 30 minutes, ce qui permet une action rapide pour déclencher la satiété de façon à limiter la quantité de nourriture à prendre lors du repas suivant .  Advantageously, the bioavailability in the body of the amino acids, peptides and proteins present in the composition is between 10 and 30 minutes, which allows a rapid action to trigger satiety so as to limit the amount of food to be taken during the meal next .
En outre, la présence de calcium de lait, avec l'alpha lactalbumine, permettent d'améliorer la palabilité du produit diététique selon l'invention en masquant notamment le goût amer de l'hydrolysat de lactosérum, de sorte qu'ils participent à supprimer le risque que les personnes cessent de le consommer pour des raisons de goût et abandonnent leur régime avant son terme.  In addition, the presence of milk calcium, with alpha lactalbumin, improve the palatability of the dietary product according to the invention by masking in particular the bitter taste of the whey hydrolyzate, so that they participate in removing the risk that people will stop eating it for reasons of taste and abandon their diet before its end.
La combinaison des acides gras, en particulier de l'EPA, avec le calcium de lait et le mélange d'acides aminés particulier selon l'invention et des biopeptides libérés, permet également de ralentir la transformation des préadipocytes en adipocytes viscéraux par régulation de MCP-1 (« Monocyte chimoattractant protein 1 »), de limiter l'action des macrophages du tissu adipeux viscéral et d'accélérer la lipolyse des adipocytes viscéraux.  The combination of fatty acids, in particular EPA, with the milk calcium and the particular amino acid mixture according to the invention and the released biopeptides, also makes it possible to slow down the transformation of the preadipocytes into visceral adipocytes by regulation of PCM. -1 ("Monocyte chemoattractant protein 1"), to limit the action of macrophages visceral adipose tissue and accelerate lipolysis of visceral adipocytes.
L'invention permet également : The invention also allows:
- de prévenir la formation et la rupture des plaques d'athérome notamment en diminuant significativement la sécrétion des adipocytokines inflammatoires, de sorte à prévenir les accidents cardiovasculaires,  to prevent the formation and rupture of atheroma plaques, in particular by significantly decreasing the secretion of inflammatory adipocytokines, so as to prevent cardiovascular events,
- de limiter le risque diabétique, notamment en faisant diminuer l'insulinorésistance qui se traduit par la baisse de l'insulinémie et et de HOMA β, HOMA S et HOMA -IR et et en faisant baisser la glycémie par une meilleure utilisation du glucose dans les muscles  - To limit the diabetic risk, in particular by decreasing the insulin resistance which results in the lowering of insulinemia and and HOMA β, HOMA S and HOMA-IR and by lowering blood glucose by a better use of glucose in muscles
- de combattre le stress chronique à la fois au niveau de l'adaptation de la personne au stress et du contrôle du cortisol.  - combat chronic stress both in terms of the person's adaptation to stress and the control of cortisol.
La composition peut donc être utilisée comme produit de santé à administration orale, agissant : The composition can therefore be used as an oral health product, acting:
- en régulant la β-oxydation des lipides, et/ou - en augmentant l'utilisation de glucose par l'organisme, et/ou by regulating the β-oxidation of lipids, and / or - by increasing the use of glucose by the body, and / or
- en diminuant l'insulino résistance et/ou  - by decreasing insulin resistance and / or
- en réduisant l'hyperperméabilité de la barrière intestinale, et/ou  by reducing the hyperpermeability of the intestinal barrier, and / or
- en ralentissant la transformation des préadipocytes en adipocytes viscéraux par régulation de MCP-1, et/ou  by slowing the transformation of the preadipocytes into visceral adipocytes by regulation of MCP-1, and / or
- en régulant l'action des macrophages du tissu adipeux viscéral, et/ou  by regulating the action of macrophages of the visceral adipose tissue, and / or
- en régulant l'inflammation des tissus adipeux et/ou  by regulating the inflammation of the adipose tissues and / or
- en accélérant la lipolyse des adipocytes viscéraux, et/ou  by accelerating the lipolysis of visceral adipocytes, and / or
- en prévenant la formation et la rupture des plaques d'athérome, et/ou  - by preventing the formation and rupture of atheromatous plaques, and / or
- en facilitant les échanges de glucose et de cholestérol et en améliorant le fonctionnement des récepteurs de leptine, insuline et triglycérides, et/ou  by facilitating the exchange of glucose and cholesterol and by improving the functioning of the leptin, insulin and triglyceride receptors, and / or
- en déclenchant l'effet de satiété.  - triggering the effect of satiety.
La composition selon l'invention, notamment la variante contenant de la metformine et/ou des statines, peut être utilisée en particulier comme médicament pour le traitement du syndrome métabolique et la prévention et/ou le traitement de maladies cardiométaboliques. En effet, une telle composition permet de traiter le syndrome métabolique en diminuant la graisse viscérale, la graisse hépatique et la graisse sous- cutanée profonde en permettant notamment une augmentation du taux d'adiponectine et de sérotonine. En particulier, la présence combinée d'au moins un principe actif pharmaceutique activateur des cycles AMPK, MAPK, PPAR a et γ et/ou SIRT1, et d'au moins un régulateur nutritionnel des cycles AMPK, MAPK, PPAR a et γ et/ou SIRT1, permet d'activer AMPK, MAPK, PPARa, PPARy et/ou SIRT1 et donc d'augmenter le niveau d'adiponectine.  The composition according to the invention, in particular the variant containing metformin and / or statins, can be used in particular as a medicament for the treatment of metabolic syndrome and the prevention and / or treatment of cardiometabolic diseases. Indeed, such a composition makes it possible to treat the metabolic syndrome by decreasing visceral fat, liver fat and deep subcutaneous fat, in particular by increasing the level of adiponectin and serotonin. In particular, the combined presence of at least one activating pharmaceutical active ingredient of the AMPK, MAPK, PPAR α and γ and / or SIRT1 cycles, and at least one nutritional regulator of the AMPK, MAPK, PPAR α and γ cycles and or SIRT1, activates AMPK, MAPK, PPARa, PPARy and / or SIRT1 and thus increases the level of adiponectin.
La composition selon l'invention peut être utilisée comme produit de santé, notamment comme médicament en prévention et traitement primaire, secondaire et tertiaire des maladies cardiométaboliques. En particulier elle peut être utilisée pour lutter contre les facteurs de risques cardiométaboliques mais aussi les maladies cardiométaboliques notamment :  The composition according to the invention can be used as a health product, especially as a medicament for prevention and primary, secondary and tertiary treatment of cardiometabolic diseases. In particular it can be used to fight cardiometabolic risk factors but also cardiometabolic diseases including:
- les maladies cardiovasculaires comme l'hypertension, l'artérite des membres inférieurs, les maladies coronariennes, les séquelles d'infarctus ou d'ictus cérébral,  - cardiovascular diseases such as hypertension, arteritis of the lower limbs, coronary heart disease, after-effects of infarction or cerebral stroke,
- l'hyperglycémie et l'insulino résistance,  - hyperglycemia and insulin resistance,
- le pré diabète de type II, - le diabète de type II, - pre diabetes type II, - type II diabetes,
- l'hyperlipidémie, et en particulier l'hyperlipidémie du diabète de type II,  - hyperlipidemia, and in particular hyperlipidemia of type II diabetes,
- la stéatose hépatique  - hepatic steatosis
- l'infertilité et/ou la sous fertilité métaboliques de l'homme et de la femme,  - the metabolic infertility and / or sub-fertility of the man and the woman,
La variante de composition contenant de la metformine et/ou une ou plusieurs statine(s) permet de faire jouer en synergie les effets pharmacologiques du ou des principe(s) actif(s) pharmaceutique(s) et les mêmes effets des principes actifs nutritionnels tels que les acides aminés et les biopeptides actifs de petite taille contenu dans Γ hydrolysat de lactosérum et l'alpha lactalbumine de même que les régulateurs nutritionnels des cycles AMPK et/ou MAPK et/ou PPAR a et γ et/ou SIRT1, et calcium de lait. La composition selon l'invention permet ainsi de conserver et même d'augmenter l'efficacité du traitement en diminuant les doses du ou des principes actifs pharmaceutiques afin de minimiser ou annuler leurs effets secondaires indésirables. The composition variant containing metformin and / or one or more statin (s) makes it possible to synergize the pharmacological effects of the active principle (s) active (s) pharmaceutical (s) and the same effects of the active ingredients nutritional such as amino acids and small active biopeptides contained in whey hydrolyzate and alpha lactalbumin as well as nutritional regulators of AMPK and / or MAPK and / or PPAR cycles a and γ and / or SIRT1, and calcium of milk. The composition according to the invention thus makes it possible to preserve and even increase the effectiveness of the treatment by reducing the doses of the pharmaceutical active ingredient (s) in order to minimize or cancel their undesirable side effects.
En effet, les principes actifs pharmaceutiques activateurs des cycles AMPK, MAPK, PPAR a et y et/ou SIRT1, comme la metformine, sont connus pour augmenter le taux d'adiponectine, mais à des doses provoquant des effets indésirables importants, notamment des myalgies musculaires pour les statines et des manifestations qui vont du simple embarras gastrique à de l'acidose lactique qui peut être fatale, en passant par la nausée et les vomissements pour la metformine.  Indeed, the activating pharmaceutical active ingredients of the AMPK, MAPK, PPAR α and γ and / or SIRT1 cycles, such as metformin, are known to increase the level of adiponectin, but at doses causing significant adverse effects, in particular myalgias. muscle for statins and manifestations ranging from simple stomach upset to lactic acidosis, which can be fatal, to nausea and vomiting for metformin.
La composition selon l'invention, notamment la variante contenant de la metformine et/ou une ou plusieurs statine(s), permet également d'améliorer la fertilité chez l'homme et la femme en surpoids, en particulier chez les personnes présentant un risque cardiométabolique, en augmentant notamment le taux d'adiponectine, de diminuer les adipocytokines inflammatoires et l'insulino résistance qui sont les facteurs déclenchant de cette infertilité et/ou sous fertilité en particulier le syndrome des ovaires polykistiques chez la femme et la quantité et qualité du sperme chez l'homme. The composition according to the invention, in particular the variant containing metformin and / or one or more statin (s), also makes it possible to improve fertility in overweight men and women, in particular in persons at risk. cardiometabolic, in particular increasing the rate of adiponectin, to decrease the inflammatory adipocytokines and the insulin resistance which are the triggering factors of this infertility and / or under fertility, in particular the syndrome of the polykistic ovaries in the woman and the quantity and quality of the sperm in the man.
La composition permet le traitement de l'infertilité et de la sous fertilité en général, en particulier de l'infertilité ou de la sous-fertilité chez l'homme ou la femme présentant une baisse de son taux d'adiponectine et/ou une augmentation des adipocytokines inflammatoires et de l'insulinémie.  The composition allows the treatment of infertility and sub-fertility in general, in particular infertility or sub-fertility in men or women with a decrease in adiponectin and / or an increase in inflammatory adipocytokines and insulinemia.
L'invention vise spécifiquement l'utilisation de la composition comme médicament pour le traitement de l'infertilité ou de la sous-fertilité chez l'homme ou la femme présentant : - un tour de taille en dehors des normes IDF 2005 (80/94 cm), et/ou The invention is specifically directed to the use of the composition as a medicament for the treatment of infertility or sub-fertility in men or women with: - a waist circumference outside the IDF 2005 standards (80/94 cm), and / or
- une insulinorésistance ou un diabète de type II, et/ou  - insulin resistance or type II diabetes, and / or
- une dyslipidémie, et/ou  - dyslipidemia, and / or
- une inflammation chronique de bas grade, et/ou  - chronic inflammation of low grade, and / or
- une stéatose hépatique, et/ou  - hepatic steatosis, and / or
- un état anxieux ou dépressif.  - an anxious or depressed state.
La composition peut être utilisée notamment :  The composition can be used in particular:
• chez la femme :  • in women:
pour lutter contre le syndrome des ovaires polykistiques et/ou l'oligoménorrhée et/ou l'aménorrhée et/ou l'hyperandrogénisme,  for combating polykistic ovary syndrome and / or oligomenorrhea and / or amenorrhea and / or hyperandrogenism,
pour permettre une reprise de l'ovulation et/ou pour améliorer la folliculogénèse et/ou pour prévenir des fausses couches spontanées.  to allow resumption of ovulation and / or to improve folliculogenesis and / or to prevent spontaneous miscarriage.
• chez l'homme :  • in humans:
pour lutter contre un dysfonctionnement érectile,  to fight against erectile dysfunction,
- pour améliorer une oligozoospermie et/ou une asthénozoospermie,  to improve oligozoospermia and / or asthenozoospermia,
pour améliorer la quantité et la mobilité des spermatozoïdes.  to improve the amount and mobility of sperm.
La composition selon l'invention est particulièrement adaptée pour le traitement de l'infertilité métabolique ou de la sous-fertilité métabolique. The composition according to the invention is particularly suitable for the treatment of metabolic infertility or metabolic sub-fertility.
Par infertilité métabolique ou sous-fertilité métabolique au sens de l'invention, en entend une infertilité ou une sous-fertilité donc la cause est un dysfonctionnement métabolique qui se traduit par un syndrome métabolique en particulier un tour de taille au-dessus des normes internationales et/ou une insulino résistance ou un diabète de type II et/ou une dyslipidémie et/ou une stéatose hépatique et/ou une inflammation chronique de bas grade et/ou un état anxieux ou dépressif. Cette infertilité métabolique se traduit cliniquement par des ovaires polykistiques, une endométriose, une anovulation, une dysovulation, une oligozoospermie, une asthénozoospermie ou un dysfonctionnement érectile.  For metabolic infertility or metabolic sub-fertility within the meaning of the invention, means infertility or sub-fertility so the cause is a metabolic dysfunction that results in a metabolic syndrome in particular a waist circumference above international standards and / or insulin resistance or type II diabetes and / or dyslipidemia and / or hepatic steatosis and / or low grade chronic inflammation and / or an anxiety or depressive state. This metabolic infertility is clinically translated by polykistic ovaries, endometriosis, anovulation, dysovulation, oligozoospermia, asthenozoospermia or erectile dysfunction.
Les différents constituants de la composition agissent en synergie pour une action très efficace sur l'amélioration de la fertilité chez l'homme ou la femme, en particulier chez l'homme ou la femme présentant un syndrome métabolique. The various constituents of the composition act in synergy for a very effective action on the improvement of fertility in men or women, in particular in men or women with a metabolic syndrome.
La composition selon l'invention est en particulier capable d'agir sur le niveau d'adiponectine, l'inflammation et l'insulinémie. Or, le niveau d'adiponectine est généralement très bas chez les personnes infertiles alors que le taux de CRPus et TNFa sont élevés ou une insulinémie élevés, notamment chez les personnes avec des ovaires polykistiques, une endométriose, une oligozoospermie, une asthénozoospermie ou un dysfonctionnement érectile. En effet, la perturbation des niveaux d'adiponectine ou de son mécanisme d'action engendré par l'inflammation est associée à une perturbation de la fertilité et de la fécondité. En effet, la régulation des adipocytokines est essentielle au maintien de l'intégrité de l'axe hypothalamo-hypophyso-ovarien, à l'ovulation, à la réussite de la nidification et du déroulement de la grossesse. L'adiponectine est liée positivement avec la SHBG et négativement avec la testostérone et le TNFa. En outre, le système reproductif est couplé avec l'équilibre énergétique. Ainsi, l'AMPK et le PPAR a et γ jouent un rôle prépondérant en intervenant dans la régulation du fonctionnement ovarien chez la femme, car ils régulent la stéroïdogenèse des cellules de la granulosa et la maturation ovocytaire. Certaines hormones impliquées dans le métabolisme utilisent l'AMPK comme molécule signal pour transmettre leurs effets centraux et ovariens sur la fonction de reproduction. Un dérèglement de ce système est à l'origine de pathologies comme le syndrome des ovaires polykistiques et l'endométriose. The composition according to the invention is in particular capable of acting on the level of adiponectin, inflammation and insulinemia. However, the level of adiponectin is generally very low in infertile persons whereas the CRPus and TNFa levels are elevated insulin levels, especially in people with polykistic ovaries, endometriosis, oligozoospermia, asthenozoospermia or erectile dysfunction. In fact, the disruption of adiponectin levels or of its mechanism of action caused by inflammation is associated with a disturbance of fertility and fertility. Indeed, the regulation of adipocytokines is essential for the maintenance of the integrity of the hypothalamic-pituitary-ovarian axis, ovulation, successful nesting and the course of pregnancy. Adiponectin is positively bound with SHBG and negatively with testosterone and TNFa. In addition, the reproductive system is coupled with energy balance. Thus, AMPK and PPAR α and γ play a major role in intervening in the regulation of ovarian function in women, since they regulate steroidogenesis of granulosa cells and oocyte maturation. Some hormones involved in metabolism use AMPK as a signal molecule to transmit their central and ovarian effects on reproductive function. Disruption of this system is at the origin of pathologies such as polykistic ovary syndrome and endometriosis.
L'augmentation du taux d'adiponectine et la baisse de l'inflammation et de l'insulino résistance permet par le jeu des cycles AMPK, MAPK, PPAR et SIRT1 :  The increase of the adiponectin rate and the decrease of the inflammation and the insulin resistance allows by the game of the cycles AMPK, MAPK, PPAR and SIRT1:
- chez les femmes, une régulation de l'ovulation ou une meilleure réponse aux traitements de stimulation de l'ovulation,  - in women, a regulation of ovulation or a better response to ovulation stimulation treatments,
- chez les hommes, une amélioration de la fonction érectile ou une augmentation de la quantité et une meilleure mobilité des spermatozoïdes,  - in men, an improvement in erectile function or an increase in the quantity and better mobility of spermatozoa,
- une action sur la testostérone : une diminution chez les femmes en ovaires polykistiques et une augmentation chez les hommes en sous-fertilité ou infertilité métabolique.  - an action on testosterone: a decrease in women in polykistic ovaries and an increase in men in sub-fertility or metabolic infertility.
L'augmentation du taux d'adiponectine et la baisse de l'inflammation et de l'insulino résistance permet ainsi avantageusement : Increasing the adiponectin level and reducing inflammation and insulin resistance thus advantageously allows:
de traiter les ovaires polykistiques, l'anovulation et dysovulation à travers l'augmentation de la phosphorylation de l'AMPK,  to treat polykistic ovaries, anovulation and dysovulation through increased phosphorylation of AMPK,
de traiter l'endométriose à travers le MAPK,  to treat endometriosis through MAPK,
- de traiter l'oligozoospermie et l'asthénozoospermie par une action sur les testicules à travers PPARy,  to treat oligozoospermia and asthenozoospermia by an action on the testes through PPARy,
de traiter le dysfonctionnement érectile à travers PPARy et NO. Par ailleurs, la composition selon l'invention est capable d'agir sur le niveau de sérotonine. Or, les femmes présentant un syndrome des ovaires polykistiques ont également un niveau bas de sérotonine. Les hommes en infertilité en raison d'un syndrome métabolique ou d'un diabète ou qui ont un dysfonctionnement érectile continu peuvent avoir un taux de sérotonine bas inférieur à 80 ng/ml responsable d'une oligospermie. to treat erectile dysfunction through PPARy and NO. Moreover, the composition according to the invention is capable of acting on the level of serotonin. However, women with polykistic ovarian syndrome also have a low level of serotonin. Men with infertility due to a metabolic syndrome or diabetes or who have continuous erectile dysfunction may have a low serotonin level of less than 80 ng / ml responsible for oligospermia.
La présence éventuellement de sélénium et de zinc agissent directement sur l'activation d'AMPK et améliorent le taux de testostérone insuffisant 6000ng/l pour l'homme et 200 ng/l pour la femme.  The presence of selenium and zinc, if they act directly on the activation of AMPK and improve the testosterone insufficient 6,000 ng / l for men and 200 ng / l for women.
Enfin, la composition selon l'invention, notamment la variante de composition comprenant la metformine et/ou une ou plusieurs statine(s), peut être utilisée spécifiquement comme produit de santé, en particulier comme médicament, pour la prévention de l'athérosclérose. L'athérosclérose est caractérisée par un dépôt de lipides sur l'intima des artères formant un noyau qui se remplit de fibres de dépôts de lipides, de cellules spumeuses et enfin de macrophages qui font sécréter des adipocytokines. La phase ultime est la calcification de la plaque d'athérome. La genèse de l'athérosclérose est la même que celle du syndrome métabolique ; il s'agit d'un excès de cholestérol, de triglycérides, d'hypertension, d'obésité abdominale, de diabète de type II, de tabagie, de stress chronique, de sédentarité et de pollution et enfin d'antécédents familiaux. Il y a donc une grande similitude entre l'athérosclérose et le syndrome métabolique, bien que la conséquence de l'athérosclérose puisse être une seule dyslipidémie liée à l'inflammation.  Finally, the composition according to the invention, in particular the composition variant comprising metformin and / or one or more statin (s), can be used specifically as a health product, in particular as a medicament, for the prevention of atherosclerosis. Atherosclerosis is characterized by a deposit of lipids on the intima of the arteries forming a nucleus which fills with fibers of lipid deposits, foam cells and finally macrophages that secrete adipocytokines. The final phase is calcification of the atheroma plaque. The genesis of atherosclerosis is the same as that of the metabolic syndrome; these include excess cholesterol, triglycerides, hypertension, abdominal obesity, type II diabetes, smoking, chronic stress, sedentary lifestyle, pollution, and family history. There is therefore a great similarity between atherosclerosis and the metabolic syndrome, although the consequence of atherosclerosis may be a single dyslipidemia related to inflammation.
Le niveau d'adiponectine est très bas et les taux d'inflammation et d'insulinémie élevés chez les personnes souffrant d'athérosclérose. L'adiponectine est déficiente en particulier en raison de l'augmentation des adipocytokines inflammatoires, notamment TNFa, qui agissent négativement à travers la transcription, la translation et le turnover d'AMPK, de MAPK, des PPAR et de SIRT1, provoquant leur baisse par déphosphorylation et donc une diminution de la sécrétion d'adiponectine.  The level of adiponectin is very low and the levels of inflammation and insulinemia are high in people with atherosclerosis. Adiponectin is deficient in particular because of the increase of inflammatory adipocytokines, in particular TNFa, which act negatively through the transcription, translation and turnover of AMPK, MAPK, PPAR and SIRT1, causing their decrease by dephosphorylation and therefore a decrease in the secretion of adiponectin.
La composition selon l'invention permet d'augmenter le taux d'adiponectine circulant et/ou de réguler sa sécrétion à long terme.  The composition according to the invention makes it possible to increase the rate of circulating adiponectin and / or to regulate its secretion in the long term.
Par ailleurs, dans l'athérosclérose la composition selon l'invention est capable d'agir sur le niveau de sérotonine.  Moreover, in atherosclerosis the composition according to the invention is capable of acting on the level of serotonin.
L'invention permet également : - de prévenir la formation et la rupture des plaques d'athérome notamment en diminuant significativement la sécrétion des adipocytokines inflammatoires, en particulier la CRP us, de sorte à prévenir les accidents cardiovasculaires, The invention also allows: to prevent the formation and rupture of atheroma plaques, in particular by significantly decreasing the secretion of inflammatory adipocytokines, in particular CRP us, so as to prevent cardiovascular events,
- de limiter le risque diabétique, notamment en restaurant l'élasticité de la membrane cellulaire par le remodelage matriciel, ce qui facilite les échanges de glucose et de cholestérol et améliore le fonctionnement des récepteurs de leptine, insuline et triglycérides, et  to limit the diabetic risk, in particular by restoring the elasticity of the cell membrane by matrix remodeling, which facilitates the exchanges of glucose and cholesterol and improves the functioning of the leptin, insulin and triglyceride receptors, and
- de combattre le stress chronique à la fois au niveau de l'adaptation de la personne au stress et du contrôle du cortisol.  - combat chronic stress both in terms of the person's adaptation to stress and the control of cortisol.
La composition selon l'invention, quelle que soit sa variante, peut donc être utilisée comme produit de santé pour différentes applications thérapeutiques. The composition according to the invention, whatever its variant, can therefore be used as a health product for different therapeutic applications.
La composition comprenant un mélange de principes actifs constitué par au moins : The composition comprising a mixture of active ingredients consisting of at least:
- un hydrolysat de lactosérum de poids moléculaire compris entre 200 et 5000 daltons,  a whey hydrolyzate with a molecular weight of between 200 and 5,000 daltons,
- de l'alpha lactalbumine,  - alpha lactalbumin,
- au moins un régulateur des cycles AMPK et/ou MAPK et/ou PPAR a et γ et/ou SIRT1, choisi parmi la famille des tocophérols, la vitamine B6, la leucine et la famille des acides aminés branchés, et  at least one regulator of the AMPK and / or MAPK and / or PPAR α and γ and / or SIRT1 cycles, chosen from the tocopherol family, vitamin B6, leucine and the branched amino acid family, and
- du calcium de lait,  - milk calcium,
peut être utilisée préférentiellement pour prévenir le risque cardiométabolique, prévenir la stéatose hépatique et/ou traiter le pré diabète et le diabète de type II, en particulier comme produit de nutrition médicale. may be used preferentially to prevent cardiometabolic risk, to prevent hepatic steatosis and / or to treat pre-diabetes and type II diabetes, particularly as a medical nutrition product.
La composition comprenant un mélange de principes actifs constitué par au moins :  The composition comprising a mixture of active ingredients consisting of at least:
- un hydrolysat de lactosérum de poids moléculaire compris entre 200 et 5000 daltons,  a whey hydrolyzate with a molecular weight of between 200 and 5,000 daltons,
- de l'alpha lactalbumine,  - alpha lactalbumin,
- au moins un activateur des cycles AMPK et/ou MAPK et/ou PPAR a et γ et/ou SIRT1, choisi parmi metformine et les statines,  at least one activator of the AMPK and / or MAPK and / or PPAR α and γ and / or SIRT1 cycles, chosen from metformin and the statins,
- au moins un régulateur des cycles AMPK et/ou MAPK et/ou PPAR a et γ et/ou SIRT1, choisi parmi la famille des tocophérols et/ou la vitamine B6, du calcium de lait, peut être utilisée préférentiellement pour prévenir le risque cardiométabolique, prévenir et/ou traiter la stéatose hépatique et/ou prévenir et/ou traiter le pré diabète et le diabète de type II, prévenir et/ou traiter les maladies cardiovasculaires, prévenir et/ou traiter l'infertilité ou la sous-fertilité, prévenir l'athérosclérose, en particulier comme médicament. L'invention est à présent illustrée par des exemples non limitatifs de compositions se présentant sous forme d'une poudre de 40 g (principes actifs et excipients) conditionnée dans un sachet, adaptées pour une utilisation comme produit de santé. at least one regulator of the AMPK and / or MAPK and / or PPAR α and γ and / or SIRT1 cycles, chosen from the family of tocopherols and / or vitamin B6, milk calcium, may be used preferentially to prevent cardiometabolic risk, prevent and / or treat hepatic steatosis and / or prevent and / or treat pre-diabetes and type II diabetes, prevent and / or treat cardiovascular disease, prevent and / or treat infertility or sub-fertility, prevent atherosclerosis, especially as a drug. The invention is now illustrated by non-limiting examples of compositions in the form of a 40 g powder (active ingredients and excipients) packaged in a bag, suitable for use as a health product.
Exemple 1 de composition, et utilisation pour la prévention du risque cardiométabolique, le pré diabète, la stéatose hépatique et la sous fertilité ou infertilité métabolique Example 1 of composition, and use for prevention of cardiometabolic risk, pre-diabetes, hepatic steatosis and sub-fertility or metabolic infertility
Cette composition est obtenue à partir des principes actifs suivants : This composition is obtained from the following active ingredients:
- 14,8 g d'hydrolysat de lactosérum de poids moléculaire entre 200 et 3500 daltons, avec un degré d'hydrolyse de 25%, soit 12 g de protéines/peptides de lactosérum,  14.8 g of whey hydrolyzate with a molecular weight between 200 and 3500 daltons, with a degree of hydrolysis of 25%, ie 12 g of protein / whey peptides,
- 13,3 g d'alpha lactalbumine, dont 12 g de protéines/peptides,  13.3 g of alpha lactalbumin, including 12 g of proteins / peptides,
- 1 mg de vitamine B6,  - 1 mg vitamin B6,
- 10 mg de vitamine E de préférence sous forme de mélange de tocophérol,  - 10 mg of vitamin E preferably in the form of a mixture of tocopherol,
- 100 μg de vitamine B9,  - 100 μg of vitamin B9,
- 2,5 μg de vitamine D,  - 2.5 μg of vitamin D,
- 750 mg d'omégas 3 sous forme d'EPA,  - 750 mg of omega 3 EPA,
- 20 mg de SOD,  20 mg of SOD,
- 25 mg de glutathion,  25 mg of glutathione
- qsp 0,28g de calcium de lait (total dans la composition 0,4 g).  - qs 0.28g of milk calcium (total in the composition 0.4 g).
Cette composition comprend dans le lactosérum et l'alpha lactalbumine : This composition comprises in whey and alpha lactalbumin:
- 2,6 g de leucine,  2.6 g of leucine,
- 1 ,4 g d'isoleucine  -1.4 g of isoleucine
- 4,3 g de glutamine  - 4.3 g of glutamine
- 0,5 g de tryptophane,  - 0.5 g of tryptophan,
- 0,6 g d'arginine.  0.6 g of arginine.
Lorsqu'on administre ce produit de nutrition médicale en cure deux fois par jour (un sachet avant le déjeuner et un sachet avant le dîner) pendant au moins 120 jours, chez des patients présentant des signes associés au risque cardiométabolique, on constate une diminution du tour de taille de l'ordre de 5% par rapport au tour de taille initial, qui se caractérise par une diminution importante de gras et en particulier de gras viscéral et sous-cutané profond. Une administration pendant 200 à 240 jours, permet une perte de 10% du tour de taille par rapport au tour de taille initial. La perte de masse grasse est usuellement plus importante que la perte de poids totale ce qui implique une augmentation relative de la masse maigre car elle ne baisse pas avec l'invention en raison de la composition et en particulier des acides aminés branchés et la leucine. La composition selon l'invention permet notamment de diminuer le gras viscéral entre 5 et 10%, selon le temps de traitement, du poids total de départ, cette diminution étant significative de la diminution du risque de maladies cardiométaboliques. Elle se traduit notamment par : When administered twice a day (one sachet before lunch and one packet before dinner) for at least 120 days in patients with signs of cardiometabolic risk, the product is administered twice daily. waist circumference of about 5% compared to the initial waistline, which is characterized by a significant decrease in fat and in particular visceral and subcutaneous fat. Administration for 200 to 240 days, allows a loss of 10% of the waist compared to the initial waist. The loss of fat mass is usually greater than the total weight loss which implies a relative increase in lean mass because it does not fall with the invention because of the composition and in particular branched amino acids and leucine. The composition according to the invention makes it possible in particular to reduce visceral fat between 5 and 10%, depending on the treatment time, of the total starting weight, this reduction being significant of the reduction of the risk of cardiometabolic diseases. It is reflected in particular by:
une diminution du taux de cholestérol Total,  a decrease in the total cholesterol level,
une diminution du taux de cholestérol LDL,  a decrease in LDL cholesterol
une hausse du taux de cholestérol HDL,  a rise in HDL cholesterol,
une diminution de triglycérides,  a decrease in triglycerides,
- une diminution de la glycémie à jeun et de la glycémie provoquée chez les patients en insulino résistance ou intolérants au glucose et de l'HbAlc chez les patients atteints de diabète de type II,  - a decrease in fasting blood glucose and blood glucose levels in patients with insulin resistance or intolerance to glucose and HbAlc in patients with type II diabetes,
- une diminution de l'insulinémie, du ΗΟΜΑβ, HOMA S et du HOMA -IR une normalisation de la tension artérielle systolique et diastolique , - une normalisation de la CRP us et du fibrinogène, et  a decrease in insulinemia, β, HOMA S and HOMA-IR normalization of systolic and diastolic blood pressure, normalization of CRP us and fibrinogen, and
une augmentation de l'adiponectine plasmatique et adipocytaire.  an increase in plasma and adipocyte adiponectin.
Exemple 2 de composition et utilisation pour la prévention / traitement du pré diabète, du diabète et de la sous fertilité et infertilité métabolique Example 2 of composition and use for the prevention / treatment of pre diabetes, diabetes and sub-fertility and metabolic infertility
Cette composition est obtenue à partir des principes actifs suivants : This composition is obtained from the following active ingredients:
- 14,8 g d'hydrolysat de lactosérum de poids moléculaire entre 200 et 3500 daltons, avec un degré d'hydrolyse de 25%, soit 12 g de protéines/peptides de lactosérum,  14.8 g of whey hydrolyzate with a molecular weight between 200 and 3500 daltons, with a degree of hydrolysis of 25%, ie 12 g of protein / whey peptides,
- 13,3 g d'alpha lactalbumine, dont 12g de protéines/peptides,  13.3 g of alpha lactalbumin, including 12 g of proteins / peptides,
- 250 mg de metformine chlorhydrate,  250 mg of metformin hydrochloride,
- 10 mg de vitamine E de préférence sous forme de mélange de tocophérol,  - 10 mg of vitamin E preferably in the form of a mixture of tocopherol,
- lmg de vitamine B6,  - lmg of vitamin B6,
- 100 μg de vitamine B9, - 2,5 μg de vitamine D, - 100 μg of vitamin B9, - 2.5 μg of vitamin D,
- qsp 280 mg de calcium de lait (total dans la composition 0,4g),  - qsp 280 mg of milk calcium (total in the composition 0.4 g),
- 25μg de sélénium,  25 μg of selenium,
- 7,5 mg de zinc,  - 7.5 mg of zinc,
- 750 mg d'omégas 3 sous forme d'EPA,  - 750 mg of omega 3 EPA,
- 20 mg de SOD,  20 mg of SOD,
- 25 mg de glutathion.  25 mg of glutathione.
Cette composition comprend : This composition comprises:
- 2,6 g de leucine,  2.6 g of leucine,
- 1 .4 g d'isoleucine,  - 1.4 g of isoleucine,
- 4.3 g de glutamine,  - 4.3 g of glutamine,
- 0,5g de tryptophane,  - 0.5g of tryptophan,
- 0,6 g d'arginine.  0.6 g of arginine.
Application de la composition 2 pour le prédiabète et diabète : Application of Composition 2 for Pre-diabetes and Diabetes:
La composition permet notamment de diminuer le gras viscéral entre 5 et 10%, selon le temps de traitement, du poids total de départ, cette diminution étant significative de la diminution du risque de maladies diabétiques . Elle se traduit notamment par : The composition makes it possible in particular to reduce the visceral fat between 5 and 10%, depending on the treatment time, of the total starting weight, this reduction being significant of the reduction of the risk of diabetic diseases. It is reflected in particular by:
une diminution de la glycémie à jeun et de la glycémie provoquée chez les patients en insulino résistance ou intolérants au glucose et de l'HbAlc chez les patients atteints de diabète de type II,  a decrease in fasting blood glucose and blood glucose levels in patients with insulin resistance or intolerance to glucose and HbAlc in patients with type II diabetes,
- une diminution de l'insulinémie, du ΗΟΜΑβ, HOMA S et du HOMA -IR  - a decrease in insulinemia, ΗΟΜΑβ, HOMA S and HOMA -IR
une normalisation de la CRP us et du fibrinogène, et  normalization of CRP us and fibrinogen, and
une augmentation de la sérotonine plasmatique,  an increase in plasma serotonin,
une augmentation de l'adiponectine plasmatique et adipocytaire. Application de la composition 2 pour la prévention et/ou le traitement de l'infertilité ou de la sous-fertilité :  an increase in plasma and adipocyte adiponectin. Application of Composition 2 for the Prevention and / or Treatment of Infertility or Sub-Fertility:
Lorsqu'on administre la composition de l'exemple 2 en cure deux fois par jour (un sachet avant le déjeuner et un sachet avant le dîner) pendant au moins 120 jours, chez des patients présentant des signes associés au risque cardiométabolique, on constate notamment une diminution du tour de taille de l'ordre de 5% par rapport au tour de taille initial, qui se caractérise par une diminution importante de gras et en particulier de gras viscéral et sous- cutané profond. Une administration pendant 200 à 240 jours, permet une perte de 10% du tour de taille par rapport au tour de taille initial. La perte de masse grasse est usuellement plus importante que la perte de poids totale ce qui implique une augmentation relative de la masse maigre. La composition selon l'invention permet notamment de diminuer le gras viscéral entre 5 et 10% (selon le temps de traitement) du poids total de départ, cette diminution étant significative de la diminution du risque de sous-fertilité et d'infertilité, en particulier de sous-fertilité et d'infertilité métabolique, et de maladies cardiométaboliques. Elle se traduit notamment par : When the composition of Example 2 is administered twice daily (one sachet before breakfast and one sachet before dinner) for at least 120 days, in patients presenting with signs associated with cardiometabolic risk, particular mention is made of a decrease in waist circumference of around 5% compared to the initial waist circumference, which characterized by a significant decrease in fat and in particular visceral and subcutaneous deep fat. Administration for 200 to 240 days, allows a loss of 10% of the waist compared to the initial waist. Fat loss is usually greater than total weight loss which implies a relative increase in lean body mass. The composition according to the invention makes it possible in particular to reduce visceral fat between 5 and 10% (depending on the treatment time) of the total starting weight, this reduction being significant of the reduction of the risk of sub-fertility and infertility, in particular. subfertility and metabolic infertility, and cardiometabolic diseases. It is reflected in particular by:
- une diminution de la testostérone libre des femmes avec des ovaires polykistiques, et/ou  - a decrease in the free testosterone of women with polykistic ovaries, and / or
- une augmentation de la progestérone, et/ou  - an increase in progesterone, and / or
- une diminution de la LH (hormone lutéinisante), et/ou  a decrease in LH (luteinizing hormone), and / or
- une suppression de l'inflammation dans l'endomètre, et/ou  - suppression of inflammation in the endometrium, and / or
- un rétablissement de la fonction érectile avec une amélioration du taux de testostérone et de l'oxyde nitrique NO, et/ou  - recovery of erectile function with improved testosterone and nitric oxide NO, and / or
- une diminution du taux de cholestérol total, et/ou  a decrease in the total cholesterol level, and / or
- une diminution du taux de cholestérol LDL, et/ou  a decrease in the LDL cholesterol level, and / or
- une stabilisation de la baisse du taux de cholestérol HDL, et/ou  a stabilization of the fall in HDL cholesterol level, and / or
- une diminution des triglycérides et/ou  - a decrease in triglycerides and / or
- une diminution de la glycémie à jeun et de la glycémie provoquée chez les personnes en insulino résistance ou intolérants au glucose, et/ou  - a decrease in fasting blood glucose and blood sugar levels in people with insulin resistance or intolerance to glucose, and / or
- une diminution l'HbAlc chez les personnes atteints de diabète de type II, et/ou - a decrease in HbAlc in people with type II diabetes, and / or
- une diminution de l'insulinémie, et/ou - a decrease in insulinemia, and / or
- une normalisation du CRP ultrasensible et du fibrinogène.  a normalization of the ultrasensitive CRP and fibrinogen.
Exemple 3 de composition et son utilisation pour la prévention primaire secondaire et tertiaire et le traitement des maladies cardiovasculaires et de l'athérosclérose Composition Example 3 and its Use for Secondary and Tertiary Primary Prevention and Treatment of Cardiovascular Diseases and Atherosclerosis
Cette composition est obtenue à partir des principes actifs suivants : This composition is obtained from the following active ingredients:
- 14,8 g d'hydrolysat de lactosérum de poids moléculaire entre 200 et 3500 daltons, avec un degré d'hydrolyse de 25%, soit 12 g de protéines/peptides de lactosérum,  14.8 g of whey hydrolyzate with a molecular weight between 200 and 3500 daltons, with a degree of hydrolysis of 25%, ie 12 g of protein / whey peptides,
- 13,3 g d'alpha lactalbumine, dont 12g de protéines/peptides, - 5 mg de simvastatine, 13.3 g of alpha lactalbumin, including 12 g of proteins / peptides, - 5 mg of simvastatin,
- 10 mg de vitamine E de préférence sous forme de mélange de tocophérol,  - 10 mg of vitamin E preferably in the form of a mixture of tocopherol,
- lmg de vitamine B6,  - lmg of vitamin B6,
- 100 μg de vitamine B9,  - 100 μg of vitamin B9,
- 2,5 μg de vitamine D,  - 2.5 μg of vitamin D,
- qsp 280 mg de calcium de lait (total dans la composition 0,4g),  - qsp 280 mg of milk calcium (total in the composition 0.4 g),
- 25μg de sélénium,  25 μg of selenium,
- 7,5 mg de zinc,  - 7.5 mg of zinc,
- 750 mg d'omégas 3 sous forme d'EPA purifiée,  - 750 mg of omega 3 in the form of purified EPA,
- 20 mg de SOD,  20 mg of SOD,
- 25 mg de glutathion.  25 mg of glutathione.
Cette composition comprend : This composition comprises:
- 2,6 g de leucine,  2.6 g of leucine,
- 1 .4 g d'isoleucine,  - 1.4 g of isoleucine,
- 4.3 g de glutamine,  - 4.3 g of glutamine,
- 0,5g de tryptophane,  - 0.5g of tryptophan,
- 0,6 g d'arginine.  0.6 g of arginine.
Application de la composition 3 pour la prévention et le traitement des maladies cardiovasculaires Application of Composition 3 for the Prevention and Treatment of Cardiovascular Diseases
Lorsqu'on administre cette composition en cure deux fois par jour (un sachet avant le déjeuner et un sachet avant le dîner) pendant au moins 120 jours, chez des patients présentant des signes associés au risque cardiovascuaires, on constate une diminution du tour de taille de l'ordre de 5% par rapport au tour de taille initial, qui se caractérise par une diminution importante de gras et en particulier de gras viscéral et sous-cutané profond. Une administration pendant 200 à 240 jours, permet une perte de 10% du tour de taille par rapport au tour de taille initial. La perte de masse grasse est usuellement plus importante que la perte de poids totale ce qui implique une augmentation relative de la masse maigre car elle ne baisse pas avec l'invention en raison de la composition et en particulier des acides aminés branchés et la leucine. La composition selon l'invention permet notamment de diminuer le gras viscéral entre 5 et 10%, selon le temps de traitement, du poids total de départ, cette diminution étant significative de la diminution du risque de maladies cardiovasculaires. Elle se traduit notamment par : When administered twice a day (one sachet before lunch and one packet before dinner) for at least 120 days, in patients with signs associated with cardiovascular risk, there is a decrease in waist circumference. of about 5% compared to the initial waistline, which is characterized by a significant decrease in fat and in particular visceral and subcutaneous fat. Administration for 200 to 240 days, allows a loss of 10% of the waist compared to the initial waist. The loss of fat mass is usually greater than the total weight loss which implies a relative increase in lean mass because it does not fall with the invention because of the composition and in particular branched amino acids and leucine. The composition according to the invention makes it possible in particular to reduce the visceral fat between 5 and 10%, depending on the treatment time, of the total starting weight, this reduction being significant for the reduction of the risk of diseases. Cardiovascular. It is reflected in particular by:
une diminution du taux de cholestérol Total,  a decrease in the total cholesterol level,
une diminution du taux de cholestérol LDL,  a decrease in LDL cholesterol
une hausse du taux de cholestérol HDL,  a rise in HDL cholesterol,
- une diminution des triglycérides,  a decrease in triglycerides,
une normalisation de la tension artérielle systolique et diastolique , une normalisation de TNFa, IL6 et CRP us et du fibrinogène, et  normalization of systolic and diastolic blood pressure, normalization of TNFa, IL6 and CRP us and fibrinogen, and
une augmentation de l'adiponectine plasmatique et adipocytaire.  an increase in plasma and adipocyte adiponectin.
Application de la composition 3 pour la prévention de l'athérosclérose Application of Composition 3 for the Prevention of Atherosclerosis
Lorsqu'on administre la composition de l'exemple 2 en cure deux fois par jour (un sachet avant le déjeuner et un sachet avant le dîner) pendant au moins 120 jours, chez des patients présentant des signes associés à l'athérosclérose et/ou au dysfonctionnement du survieillissement métabolique, on constate une diminution du tour de taille de l'ordre de 5% par rapport au tour de taille initial, qui se caractérise par une diminution importante de gras et en particulier de gras viscéral et sous-cutané profond. Une administration pendant 200 à 240 jours, permet une perte de 10% du tour de taille par rapport au tour de taille initial. La perte de masse grasse est usuellement plus importante que la perte de poids totale ce qui implique une augmentation relative de la masse maigre. La composition selon l'invention permet notamment de diminuer le gras viscéral entre 5 et 10%, selon le temps de traitement, du poids total de départ, cette diminution étant significative de la diminution de l'athérosclérose. Elle se traduit notamment par : When administering the composition of Example 2 in a course of treatment twice a day (a sachet before lunch and a sachet before dinner) for at least 120 days, in patients presenting signs associated with atherosclerosis and / or In the dysfunction of the metabolic over-aging, there is a decrease in waist circumference of the order of 5% compared to the initial waistline, which is characterized by a significant decrease in fat and in particular deep visceral and subcutaneous fat. Administration for 200 to 240 days, allows a loss of 10% of the waist compared to the initial waist. Fat loss is usually greater than total weight loss which implies a relative increase in lean body mass. The composition according to the invention makes it possible in particular to reduce the visceral fat between 5 and 10%, depending on the treatment time, of the total starting weight, this reduction being significant of the decrease in atherosclerosis. It is reflected in particular by:
une diminution du taux de cholestérol Total,  a decrease in the total cholesterol level,
une diminution du taux de cholestérol LDL,  a decrease in LDL cholesterol
une augmentation du taux de cholestérol HDL,  an increase in HDL cholesterol,
- une diminution des triglycérides,  a decrease in triglycerides,
une diminution de l'insulinorésistance,  a decrease in insulin resistance,
une normalisation de la tension artérielle systolique et diastolique, une amélioration des facteurs de l'homéostasie comme le fibrinogène, un remodelage matriciel avec une amélioration de l'élasticité membranaire, - une normalisation de la CRP us et des marqueurs plasmatiques et adipocytaires de l'inflammation augmentation de l'adiponectine adipocytaire et plasmatique augmentation de la sérotonine. normalization of systolic and diastolic blood pressure, improvement of homeostasis factors such as fibrinogen, matrix remodeling with improved membrane elasticity, normalization of CRP us and plasma and adipocyte markers of inflammation increased adipocyte adipocyte and plasma serotonin increase.
Exemple 4 de composition et utilisation pour le traitement des maladies cardiovasculaires avec diabète de type II ou diabète avec un risque cardiovasculaire Example 4 of composition and use for the treatment of cardiovascular diseases with type II diabetes or diabetes with cardiovascular risk
Cette composition est obtenue à partir des principes actifs suivants : This composition is obtained from the following active ingredients:
- 14,8 g d'hydrolysat de lactosérum de poids moléculaire entre 200 et 3500 daltons, avec un degré d'hydrolyse de 25%, soit 12 g de protéines/peptides de lactosérum,  14.8 g of whey hydrolyzate with a molecular weight between 200 and 3500 daltons, with a degree of hydrolysis of 25%, ie 12 g of protein / whey peptides,
- 13,3 g d'alpha lactalbumine, dont 12g de protéines/peptides,  13.3 g of alpha lactalbumin, including 12 g of proteins / peptides,
- 2.5 mg d'atorvastatine,  - 2.5 mg of atorvastatin,
- 10 mg de vitamine E de préférence sous forme de mélange de tocophérol,  - 10 mg of vitamin E preferably in the form of a mixture of tocopherol,
- lmg de vitamine B6,  - lmg of vitamin B6,
- 100 μg de vitamine B9,  - 100 μg of vitamin B9,
- 2,5 μg de vitamine D,  - 2.5 μg of vitamin D,
- qsp 280 mg de calcium de lait (total dans la composition 0,4g),  - qsp 280 mg of milk calcium (total in the composition 0.4 g),
- 25μg de sélénium,  25 μg of selenium,
- 7,5 mg de zinc,  - 7.5 mg of zinc,
- 750 mg d'omégas 3 sous forme d'EPA purifiée,  - 750 mg of omega 3 in the form of purified EPA,
- 20 mg de SOD,  20 mg of SOD,
- 25 mg de glutathion.  25 mg of glutathione.
Cette composition comprend : This composition comprises:
- 2,6 g de leucine,  2.6 g of leucine,
- 1 .4 g d'isoleucine,  - 1.4 g of isoleucine,
- 4.3 g de glutamine,  - 4.3 g of glutamine,
- 0,5g de tryptophane,  - 0.5g of tryptophan,
- 0,6 g d'arginine.  0.6 g of arginine.
Application dans les maladies cardiovasculaires avec diabète ou diabète avec un risque cardiovasculaire en particulier des triglycérides élevés  Application in cardiovascular diseases with diabetes or diabetes with a cardiovascular risk especially high triglycerides
Lorsqu'on administre la composition de l'exemple 2 en cure deux fois par jour (un sachet avant le déjeuner et un sachet avant le dîner) pendant au moins 120 jours, chez des patients présentant des signes associés à l'athérosclérose et/ou au dysfonctionnement du survieillissement métabolique, on constate une diminution du tour de taille de l'ordre de 5% par rapport au tour de taille initial, qui se caractérise par une diminution importante de gras et en particulier de gras viscéral et sous-cutané profond. Une administration pendant 200 à 240 jours, permet une perte de 10% du tour de taille par rapport au tour de taille initial. La perte de masse grasse est usuellement plus importante que la perte de poids totale ce qui implique une augmentation relative de la masse maigre. La composition selon l'invention permet notamment de diminuer le gras viscéral entre 5 et 10%, selon le temps de traitement, du poids total de départ, cette diminution étant significative de la diminution des risques liés au diabète surtout associé à des triglycérides élevés qui selon les études de prévalence sont les associations les plus dangereuses pour un accident cardiovasculaire . Elle se traduit notamment par : When administering the composition of Example 2 in a course of treatment twice a day (a sachet before lunch and a sachet before dinner) for at least 120 days, in patients presenting signs associated with atherosclerosis and / or at the dysfunction of the metabolic survivalillissement, one notes a decrease in the circumference of the order of 5% compared to the initial waistline, which is characterized by a significant decrease in fat and in particular visceral and subcutaneous deep fat. Administration for 200 to 240 days, allows a loss of 10% of the waist compared to the initial waist. Fat loss is usually greater than total weight loss which implies a relative increase in lean body mass. The composition according to the invention makes it possible in particular to reduce the visceral fat between 5 and 10%, depending on the treatment time, of the total starting weight, this reduction being significant of the reduction of the risks related to diabetes especially associated with high triglycerides which according to prevalence studies are the most dangerous associations for a cardiovascular event. It is reflected in particular by:
une diminution du taux de cholestérol Total,  a decrease in the total cholesterol level,
une diminution du taux de cholestérol LDL,  a decrease in LDL cholesterol
une augmentation du taux de cholestérol HDL,  an increase in HDL cholesterol,
une diminution des triglycérides,  a decrease in triglycerides,
- une diminution de la glycémie à jeun et de la glycémie provoquée chez les patients en insulino résistance ou intolérants au glucose et de l'HbAlc chez les patients atteints de diabète de type II,  - a decrease in fasting blood glucose and blood glucose levels in patients with insulin resistance or intolerance to glucose and HbAlc in patients with type II diabetes,
- une diminution de l'insulinémie, du ΗΟΜΑβ, HOMA S et du HOMA -IR une normalisation de la tension artérielle,  - a decrease in insulinemia, ΗΟΜΑβ, HOMA S and HOMA -IR normalization of blood pressure,
- une amélioration des facteurs de l'homéostasie comme le fibrinogène, un remodelage matriciel avec une amélioration de l'élasticité membranaire, une normalisation de la CRP us et des marqueurs plasmatiques et adipocytaires de l'inflammation  - Improvement of homeostasis factors such as fibrinogen, matrix remodeling with improved membrane elasticity, normalization of CRP us and plasma and adipocyte markers of inflammation
augmentation de l'adiponectine adipocytaire et plasmatique  adipocyte and plasma adiponectin increase
- une augmentation de la sérotonine plasmatique.  - an increase in plasma serotonin.
L'utilisation de la composition selon l'invention, quelle que soit sa variante, comme produit de santé est accompagnée d'un changement de mode de vie pour améliorer encore ses effets. En effet, dans les maladies chroniques, la problématique est plus compliquée que dans le cas d'une maladie aiguë où il suffit généralement de poser le diagnostic, de formuler le traitement, d'en informer le patient et de suivre à travers des analyses les résultats du traitement et de l'adapter si nécessaire. La composition selon l'invention est donc préférentiellement utilisée comme produit de santé en complément d'un changement de mode vie permettant d'appuyer le traitement dans le cadre de l'augmentation de l'adiponectine et de la sérotonine , de la diminution de l'insulinémie et de l'inflammation en particulier. The use of the composition according to the invention, whatever its variant, as a health product is accompanied by a change in lifestyle to further enhance its effects. Indeed, in chronic diseases, the problem is more complicated than in the case of an acute disease where it is usually enough to make the diagnosis, to formulate the treatment, to inform the patient and to follow through analyzes the treatment results and adapt it if necessary. The composition according to the invention is therefore preferably used as a health product in addition to a change in lifestyle to support the treatment in the context of the increase in adiponectin and serotonin, the decrease in insulinemia and inflammation in particular.
La composition selon l'invention est préférentiellement utilisée comme produit de santé en complément : The composition according to the invention is preferably used as a health product in addition to:
- d'une alimentation particulière,  - a particular diet,
- d'une restriction calorique adaptée, et/ou  - a suitable calorie restriction, and / or
- d'une gestion du stress chronique, et/ou  - chronic stress management, and / or
- d'une gestion de la tendance anxieuse ou dépressive, et/ou  - management of the anxious or depressive tendency, and / or
- d'une activité physique et de la lutte contre la sédentarité.  - Physical activity and the fight against a sedentary lifestyle.
L'alimentation doit notamment comprendre une consommation de glucides à charges glycémiques (ou index glycémique) basses en général inférieure à 20 et/ou une consommation de fibres solubles et insolubles et/ou une suppression des acides gras saturés et le remplacement partiel de ces acides gras saturés par des acides gras polyinsaturés et/ou une consommation d'acides gras oméga 3, et/ou la suppression des produits de glycation (par réaction de Maillard).  The diet should in particular include a consumption of carbohydrates with a low glycemic load (or glycemic index) in general of less than 20 and / or a consumption of soluble and insoluble fibers and / or a suppression of saturated fatty acids and the partial replacement of these acids. saturated fats with polyunsaturated fatty acids and / or consumption of omega 3 fatty acids, and / or the suppression of glycation products (by Maillard reaction).
L'objectif d'une telle alimentation est de limiter la glycémie post prandiale et les pics d'inflammation afférents source d'accidents cardiovasculaires, de limiter l'oxydation excessives des glucides, de baisser l'inflammation des adipocytokines, de provoquer l'arrêt de la transformation des préadipocytes en adipocytes et l'infiltration des macrophages et enfin la lipolyse des adipocytes viscéraux.  The goal of such a diet is to limit postprandial blood glucose and related inflammation peaks that cause cardiovascular events, to limit the excessive oxidation of carbohydrates, to lower the inflammation of adipocytokines, to stop from the transformation of preadipocytes into adipocytes and the infiltration of macrophages and finally the lipolysis of visceral adipocytes.
La limitation drastique des produits de glycation permet de baisser l'inflammation, ceci demande un changement souvent radical des modes de cuisson en particulier des fritures. L'apport en omégas 3 et protéines animales non grasses de poisson et de viande blanche permet aussi de favoriser la lipolyse en particulier au niveau hépatique. De plus il augmente significativement l'adiponectine.  The drastic limitation of the glycation products makes it possible to lower the inflammation, this requires a change that is often radical in the cooking methods, in particular fried foods. The intake of omega 3 and non-fat animal protein from fish and white meat can also promote lipolysis especially in the liver. In addition, it significantly increases adiponectin.
Par ailleurs, une consommation modérée de vin rouge (1 verre par jour) permet d'améliorer l'augmentation du taux d'adiponectine.  In addition, moderate consumption of red wine (1 drink per day) improves the increase in adiponectin levels.
Concernant la restriction calorique, elle permet d'augmenter SIRTl et joue donc en faveur d'une augmentation du taux d'adiponectine. Il faut toutefois veiller à ce que la diète ne soit pas trop restrictive, notamment très en-dessous de la dépense énergétique de base, car la réaction au niveau cellulaire sera violente par blocage du ratio AMP/ATP à travers AMPK et PPARy et provoquera un rebond dès l'arrêt de la restriction calorique. Regarding caloric restriction, it increases SIRT1 and therefore promotes an increase in adiponectin levels. However, care must be taken to ensure that the diet is not too restrictive, particularly well below the basic energy Reaction at the cellular level will be violent by blocking the AMP / ATP ratio across AMPK and PPARy and will cause a rebound upon stopping the caloric restriction.
La gestion du stress chronique est préférentiellement réalisée par des méthodes holistiques ou encore des activités physiques spécifiques ou générales pour faire baisser le cortisol circulant. Cette gestion du stress chronique permet d'avoir un impact sur AMPK, MAPK, PPARy et SIRTl. The management of chronic stress is preferably carried out by holistic methods or specific or general physical activities to lower the circulating cortisol. This chronic stress management has an impact on AMPK, MAPK, PPARy and SIRTl.
La gestion de la tendance anxieuse ou dépressive peut être réalisée par des méthodes holistiques ou encore des activités physiques spécifiques ou générales. L'apport de tryptophane et donc de sérotonine permet d'améliorer le fond anxieux ou dépressif commun à des nombreuses personnes en surpoids. De même par la production de sérotonine cérébrale la qualité du sommeil est améliorée. Enfin par la perte de poids et de masse grasse les apnées du sommeil disparaissent souvent.  The management of the anxious or depressive tendency can be achieved by holistic methods or specific or general physical activities. The intake of tryptophan and therefore serotonin can improve the anxiety or depressive background common to many overweight people. Similarly by the production of cerebral serotonin the quality of sleep is improved. Finally by weight loss and fat mass sleep apnea often disappear.
Enfin, l'activité physique et la lutte contre la sédentarité, est un facteur important, qui permet notamment d'augmenter AMPK et SIRTl et donc l'adiponectine sur le long terme. L'activité physique doit être modérée et de 30 minutes minimum. Par contre les activités intenses et prolongées (comme le marathon) sont source de grande oxydation.  Finally, physical activity and the fight against sedentary lifestyle is an important factor, which makes it possible to increase AMPK and SIRT1 and therefore adiponectin over the long term. Physical activity should be moderate and 30 minutes minimum. On the other hand, intense and prolonged activities (like the marathon) are a source of great oxidation.
La restriction calorique et l'augmentation de l'activité physique agissent sur les cycles AMPK, PPAR et SIRTl d'une manière significative et inversement, l'augmentation biochimique d'AMPK, PPAR et SIRTl mime l'action de la restriction calorique et de l'activité physique. C'est pourquoi la combinaison d'une composition capable d'augmenter notamment d'AMPK, PPAR et SIRTl et d'une restriction calorique associée à une activité physique a un impact extrêmement favorable sur la prévention des facteurs de risque cardiométabolique, de la stéatose hépatique et le traitement du pré diabète. Caloric restriction and increased physical activity act on the AMPK, PPAR and SIRT1 cycles in a significant way and conversely, the biochemical increase of AMPK, PPAR and SIRT1 mimics the action of caloric restriction and physical activity. This is why the combination of a composition capable of increasing AMPK, PPAR and SIRTl, and a caloric restriction associated with physical activity has an extremely favorable impact on the prevention of cardiometabolic and steatosis risk factors. hepatic and pre diabetes treatment.
Cette utilisation de la composition complémentée par un changement de mode de vie (adaptation de l'alimentation et/ou restriction calorique et/ou augmentation de l'activité physique et de la lutte contre la sédentarité et/ou gestion du stress et/ou gestion des états anxieux ou dépressifs) demande une prise en charge par lui-même du patient qui nécessite en particulier une éducation thérapeutique du patient.  This use of the composition supplemented by a change in lifestyle (adaptation of diet and / or caloric restriction and / or increase in physical activity and the fight against sedentary lifestyle and / or stress management and / or management anxious or depressive states) requires self-management of the patient which requires in particular a therapeutic education of the patient.
Selon une variante adaptée de l'invention, l'utilisation de la composition produit de santé est accompagnée par un procédé comprenant notamment :  According to an adapted variant of the invention, the use of the health product composition is accompanied by a process comprising in particular:
- la détermination d'un objectif de diminution de tour de taille,  - the determination of a waistline reduction target,
- la formation du patient à un changement de mode de vie. L'éducation thérapeutique du patient nécessite deux conditions : - training the patient in a lifestyle change. Therapeutic patient education requires two conditions:
- la motivation du patient,  - the motivation of the patient,
- la formation du patient à l'éducation thérapeutique.  - training the patient in therapeutic education.
La motivation du patient dans le cadre de la santé est difficile à mettre en œuvre lorsqu'il s'agit d'un changement de mode de vie, surtout s'il est visé un changement de plus de 20% des habitudes qui sont ancrées dans la personnalité du patient (famille, région, religion, milieu social, milieu professionnel, etc.).  Patient motivation in the health setting is difficult to implement when it comes to lifestyle change, especially if it is aimed at a change of more than 20% of habits that are rooted in the patient's personality (family, region, religion, social milieu, professional environment, etc.).
De façon préférée, l'utilisation de la composition comme produit de santé est également accompagnée de la détermination d'un objectif de diminution de tour de taille.  Preferably, the use of the composition as a health product is also accompanied by the determination of a waistline reduction target.
La motivation du patient à un travers un objectif de diminution de tour de taille, lui donne un objectif simple dans sa recherche de prévention ou de traitement, The motivation of the patient to one through a goal of decreasing waist circumference, gives him a simple goal in his search for prevention or treatment,
Concernant la formation du patient à l'éducation thérapeutique, la difficulté réside dans le nombre de personnes concernées, puisque le syndrome métabolique concerne 25 à 35% de la population adulte soit des millions de personnes. Or, les structures médicales et paramédicales ne sont pas capables de former une telle masse de population. Il est donc préférée d'avoir recours à l'e-santé de façon personnalisée mais également standardisée par phénotypes car le contact doit être fréquent, idéalement journalier.  Regarding the training of the patient in therapeutic education, the difficulty lies in the number of people concerned, since the metabolic syndrome affects 25 to 35% of the adult population is millions of people. However, the medical and paramedical structures are not capable of forming such a mass of population. It is therefore preferable to use e-health in a personalized way but also standardized by phenotypes because the contact must be frequent, ideally every day.
Préférentiellement, l'utilisation de la composition comme produit de santé est également accompagnée d'une formation du patient à un changement de mode de vie par l'exemple et par effet d'entraînement.  Preferentially, the use of the composition as a health product is also accompanied by training the patient in a lifestyle change by example and by training effect.
En particulier, l'utilisation de la composition comme produit de santé peut être accompagnée par un enseignement thérapeutique d'e-santé, notamment par l'utilisation d'un jeu vidéo médical dans lequel un avatar du patient évolue comme son modèle. Le patient renseigne ses données médicales et leurs évolutions, ainsi que les informations concernant la prise du produit de santé, son alimentation, sa restriction calorique, son stress chronique, sa tendance dépressive et sa médication pharmacologique si nécessaire. L'avatar réagit comme le patient qui recevra alors des messages en fonction de son évolution positive ou négative. Chaque évolution de l'avatar est expliquée avec un enseignement sur les points positifs ou négatifs.  In particular, the use of the composition as a health product can be accompanied by a therapeutic e-health teaching, in particular by the use of a medical video game in which an avatar of the patient evolves as his model. The patient provides information on their medical data and evolutions, as well as information on the health product's intake, diet, caloric restriction, chronic stress, depressive tendency and pharmacological medication if necessary. The avatar reacts like the patient who will then receive messages according to his positive or negative evolution. Each evolution of the avatar is explained with a teaching on the positive or negative points.
L'invention vise donc également l'utilisation de la composition comme produit de santé accompagnée par un procédé d'éducation thérapeutique comprenant notamment : - la motivation du patient par la détermination d'un objectif de diminution de tour de taille, et/ou The invention therefore also relates to the use of the composition as a health product accompanied by a method of therapeutic education including in particular: - the motivation of the patient by the determination of a waistline reduction target, and / or
- la formation du patient à un changement de mode de vie par la création de son avatar dans un jeu vidéo médicalisé qui réagit comme lui et dont il doit tirer les enseignements.  - The training of the patient in a change of lifestyle by creating his avatar in a medical video game that reacts like him and from which he must learn.
Ceci permet encore d'améliorer l'efficacité de la composition selon l'invention.  This further improves the effectiveness of the composition according to the invention.

Claims

REVENDICATIONS
1. Composition, adaptée pour une utilisation comme produit de santé à administration orale, comprenant un mélange de principes actifs constitué par au moins : A composition, adapted for use as an oral health product, comprising a mixture of active ingredients consisting of at least:
- un hydrolysat de lactosérum de poids moléculaire compris entre 200 et 5000 daltons,  a whey hydrolyzate with a molecular weight of between 200 and 5,000 daltons,
- de l'alpha lactalbumine,  - alpha lactalbumin,
- au moins un régulateur des cycles AMPK et/ou MAPK et/ou PPAR a et γ et/ou SIRTl choisi parmi la famille des tocophérols, la vitamine B6, la leucine et la famille des acides branchés, et  at least one regulator of the AMPK and / or MAPK and / or PPAR cycles α and γ and / or SIRT1 chosen from the family of tocopherols, vitamin B6, leucine and the family of branched acids, and
- du calcium de lait.  - milk calcium.
2. Composition selon la revendication 1, caractérisée en ce que 55% du total des molécules de l'hydrolysat de lactosérum a un poids moléculaire inférieur ou égal à 1000 daltons.  2. Composition according to claim 1, characterized in that 55% of the total molecules of the whey hydrolyzate has a molecular weight less than or equal to 1000 daltons.
3. Composition selon l'une des précédentes revendications, caractérisée en ce que l'hydrolysat de lactosérum a un degré d'hydrolyse compris entre 15% et 35%.  3. Composition according to one of the preceding claims, characterized in that the whey hydrolyzate has a degree of hydrolysis of between 15% and 35%.
4. Composition selon l'une des précédentes revendications, caractérisée en ce que le ratio en poids de protéines entre l'alpha lactalbumine et l'hydrolysat de lactosérum est compris entre 50/50 et 30/70.  4. Composition according to one of the preceding claims, characterized in that the weight ratio of proteins between alpha lactalbumin and whey hydrolyzate is between 50/50 and 30/70.
5. Composition selon l'une des précédentes revendications, caractérisée en ce que la quantité de régulateur(s) des cycles AMPK et/ou MAPK et/ou PPAR a et γ et/ou SIRTl choisi(s) parmi la famille des tocophérols, la vitamine B6, la leucine et la famille des acides branchés est de 5 à 30 mg pour entre 25 et 40 g de composition.  5. Composition according to one of the preceding claims, characterized in that the amount of regulator (s) AMPK cycles and / or MAPK and / or PPAR a and γ and / or SIRT1 chosen (s) from the family of tocopherols, vitamin B6, leucine and the family of branched acids is from 5 to 30 mg for between 25 and 40 g of composition.
6. Composition selon l'une des précédentes revendications, caractérisée en ce que la composition comprend au moins un des acides aminés choisis parmi le tryptophane, la glutamine, la leucine, l'isoleucine et l'arginine, ces acides aminés étant issus des constituants du mélange de principe actif.  6. Composition according to one of the preceding claims, characterized in that the composition comprises at least one of the amino acids selected from tryptophan, glutamine, leucine, isoleucine and arginine, these amino acids being derived from the constituents of the active ingredient mixture.
7. Composition selon la revendication 6, caractérisée en que le tryptophane représente entre 6 et 9% en poids des acides aminés neutres présents dans la composition. 7. Composition according to claim 6, characterized in that the tryptophan represents between 6 and 9% by weight of the neutral amino acids present in the composition.
8. Composition selon l'une des précédentes revendications, caractérisée en ce que le mélange de principes actifs comprend également au moins un des éléments ajoutés librement choisis parmi la vitamine B9 et la vitamine D. 8. Composition according to one of the preceding claims, characterized in that the active ingredient mixture also comprises at least one of the elements added freely selected from vitamin B9 and vitamin D.
9. Composition selon l'une des précédentes revendications, caractérisée en ce que le mélange de principes actifs comprend également des acides gras essentiels.  9. Composition according to one of the preceding claims, characterized in that the active ingredient mixture also comprises essential fatty acids.
10. Composition selon la revendication 9, caractérisée en ce que les acides gras essentiels sont des omégas 3 d'origine végétale ALA, avec une proportion élevée d'EPA ou encore de l'EPA purifié.  10. Composition according to claim 9, characterized in that the essential fatty acids are omega 3 of plant origin ALA, with a high proportion of EPA or purified EPA.
11. Composition selon l'une des précédentes revendications, caractérisée en ce que l'hydrolysat de lactosérum représente entre 40 et 60%, l'alpha lactalbumine entre 38 et 55%, et le calcium de lait entre 1 et 3%, les pourcentages étant donnés en poids de matière sèche de la totalité des principes actifs présents de la composition.  11. Composition according to one of the preceding claims, characterized in that the whey hydrolyzate represents between 40 and 60%, the alpha lactalbumin between 38 and 55%, and the milk calcium between 1 and 3%, the percentages given by weight of dry matter of all the active ingredients present in the composition.
12. Composition selon l'une des précédentes revendications, caractérisée en ce qu'elle est constituée par au moins :  12. Composition according to one of the preceding claims, characterized in that it consists of at least:
- 1 à 3% de tryptophane,  - 1 to 3% of tryptophan,
- 12 à 20 % d'acides aminés branchés,  12 to 20% of branched amino acids,
- 6 à 10 % d'acides aminés aromatiques,  6 to 10% of aromatic amino acids,
- 10 et 20% de glutamine ou d'acide glutamique,  - 10 and 20% glutamine or glutamic acid,
- 1,6 à 3% d'arginine,  - 1.6 to 3% arginine,
- 1,2 à 3% de calcium de lait,  - 1.2 to 3% milk calcium,
- 0,2 à 1% d'EPA,  0.2 to 1% EPA,
- 1 à 2 mg de vitamine B6 pour 30g de composition sans excipients,  1 to 2 mg of vitamin B6 for 30 g of composition without excipients,
- 1 à 3 μg de vitamine D pour 30g de composition sans excipients,  1 to 3 μg of vitamin D for 30 g of composition without excipients,
- 75 à 150 μg de vitamine B9 pour 30g de composition sans excipients, - 5 à 15 mg de vitamine E pour 30g de composition sans excipients, les pourcentages étant donnés en poids de matière sèche de la totalité des principes actifs présents de la composition.  75 to 150 μg of vitamin B9 per 30 g of composition without excipients, 5 to 15 mg of vitamin E per 30 g of composition without excipients, the percentages being given by weight of dry matter of all the active ingredients present in the composition.
13. Composition selon l'une des précédentes revendications, caractérisée en ce qu'elle se présente sous forme de poudre, granules, comprimés, gélules ou sous forme liquide.  13. Composition according to one of the preceding claims, characterized in that it is in the form of powder, granules, tablets, capsules or in liquid form.
14. Composition selon l'une des précédentes revendications, caractérisée en ce qu'elle comprend également au moins un principe actif pharmaceutique régulateur des cycles AMPK et/ou MAPK et/ou et/ou PPAR a et γ et/ou SIRTl choisi parmi la metformine et les statines. 14. Composition according to one of the preceding claims, characterized in that it also comprises at least one active ingredient pharmaceutical regulator of AMPK and / or MAPK and / or and / or PPAR α and γ and / or SIRT1 cycles selected from among metformin and statins.
15. Composition selon la revendication 14, caractérisée en ce que le au moins un régulateur des cycles AMPK, MAPK, PPAR a et γ et/ou SIRTl choisi parmi la simvastatine et/ou pravastatine et/ou rosuvastatine et/ou atorvastatine et/ou fluvastatine et/ou lovastatine.  15. Composition according to claim 14, characterized in that the at least one regulator of the AMPK, MAPK, PPAR α and γ and / or SIRT1 cycles chosen from simvastatin and / or pravastatin and / or rosuvastatin and / or atorvastatin and / or fluvastatin and / or lovastatin.
16. Composition selon l'une revendications 14 ou 15, caractérisée en ce que la quantité du au moins un principe actif pharmaceutique régulateur des cycles AMPK et/ou MAPK et/ou et/ou PPAR a et γ et/ou SIRTl est de 200 à 700 mg pour la metformine et pour entre 2.5 à 10 mg pour les statines, pour entre 20 et 40 g de composition sans excipients.  16. Composition according to one of claims 14 or 15, characterized in that the amount of the at least one active pharmaceutical ingredient regulating AMPK cycles and / or MAPK and / or and / or PPAR a and γ and / or SIRT1 is 200. 700 mg for metformin and for between 2.5 to 10 mg for statins, for between 20 and 40 g of composition without excipients.
17. Composition selon l'une des précédentes revendications, caractérisée en ce qu'elle est constituée par au moins :  17. Composition according to one of the preceding claims, characterized in that it consists of at least:
1 à 3% de tryptophane,  1 to 3% tryptophan,
12 à 20 % d'acides aminés branchés,  12 to 20% of branched amino acids,
- 6 à 10 % d'acides aminés aromatiques,  6 to 10% of aromatic amino acids,
10 et 20% de glutamine ou d'acide glutamique,  10 and 20% of glutamine or glutamic acid,
1,6 à 3% d'arginine,  1.6 to 3% arginine,
1,2 à 3% de calcium de lait,  1.2 to 3% milk calcium,
200 à 600mg de metformine et/ou 5 à 20 mg de simvastatine et/ou 2.5 à 5 mg d'atorvastatine pour 20 à 40g de composition sans excipients,  200 to 600 mg of metformin and / or 5 to 20 mg of simvastatin and / or 2.5 to 5 mg of atorvastatin for 20 to 40 g of composition without excipients,
0,2 à 1% d'EPA,  0.2 to 1% EPA,
1 à 2 mg de vitamine B6 pour 30g de composition sans excipients,  1 to 2 mg of vitamin B6 for 30 g of composition without excipients,
1 à 3 μg de vitamine D pour 30g de composition sans excipients,  1 to 3 μg of vitamin D for 30 g of composition without excipients,
75 à 150 μg de vitamine B9 pour 30g de composition sans excipients,  75 to 150 μg of vitamin B9 for 30 g of composition without excipients,
- 5 à 15 mg de vitamine E pour 30g de composition sans excipients,  5 to 15 mg of vitamin E for 30 g of composition without excipients,
les pourcentages étant donnés en poids de matière sèche de la totalité des principes actifs présents de la composition. the percentages being given by dry weight of all the present active ingredients of the composition.
18. Composition selon l'une des précédentes revendications, pour son utilisation comme produit de santé à administration orale.  18. Composition according to one of the preceding claims, for its use as an oral health product.
19. Composition pour son utilisation selon la revendication 18, caractérisée en ce que le produit de santé est un produit de nutrition médicale ou un médicament à administration orale. 19. Composition for use according to claim 18, characterized in that the health product is a medical nutrition product or an oral drug.
20. Composition pour son utilisation selon l'une des revendications 18 ou 19, dans la prévention de la stéatose hépatique et/ou dans le traitement du pré diabète de type II. 20. Composition for its use according to one of claims 18 or 19, in the prevention of hepatic steatosis and / or in the treatment of pre-type II diabetes mellitus.
21. Composition pour son utilisation selon l'une des revendications 18 ou 19, dans la lutte contre le diabète de type II.  21. Composition for its use according to one of claims 18 or 19, in the fight against type II diabetes.
22. Composition pour son utilisation selon la revendication 18 ou 19, dans le traitement de l'infertilité et/ou la sous-fertilité chez l'homme ou la femme en surpoids.  22. A composition for use as claimed in claim 18 or 19 in the treatment of infertility and / or sub-fertility in overweight men or women.
23. Composition pour son utilisation selon la revendication 22, dans le traitement de l'infertilité et/ou la sous-fertilité chez l'homme ou la femme présentant une baisse de son taux d'adiponectine et/ou de son taux de sérotonine.  23. Composition for its use according to claim 22, in the treatment of infertility and / or sub-fertility in men or women with a decrease in its adiponectin and / or serotonin levels.
24. Composition pour son utilisation selon la revendication 22 ou 23, dans le traitement de l'infertilité et/ou la sous-fertilité chez l'homme ou la femme présentant :  24. Composition for its use according to claim 22 or 23, in the treatment of infertility and / or sub-fertility in men or women with:
- un tour de taille en dehors des normes IDF 2005, et/ou  - a waist circumference outside the IDF 2005 standards, and / or
- une insulino-résistance ou un diabète de type II, et/ou  - insulin resistance or type II diabetes, and / or
- une dyslipidémie, et/ou  - dyslipidemia, and / or
- une inflammation chronique de bas grade, et/ou  - chronic inflammation of low grade, and / or
- une stéatose hépatique, et/ou  - hepatic steatosis, and / or
- un état dépressif ou en état de dépression.  - Depressive state or depression.
25. Composition pour son utilisation selon l'une des revendications 22 à 24, dans le traitement du syndrome des ovaires polykistiques et/ou de l'oligoménorrhée et/ou de l'aménorrhée et/ou de l'hyperandrogénisme ou dans la lutte contre un dysfonctionnement érectile et/ou une oligozoospermie et/ou une asthénozoospermie.  25. Composition for its use according to one of claims 22 to 24, in the treatment of polykistic ovarian syndrome and / or oligomenorrhea and / or amenorrhea and / or hyperandrogenism or in the fight against erectile dysfunction and / or oligozoospermia and / or asthenozoospermia.
26. Composition pour son utilisation selon l'une des revendications 18 ou 19, dans la prévention et/ou le traitement de maladies cardiométaboliques.  26. Composition for its use according to one of claims 18 or 19, in the prevention and / or treatment of cardiometabolic diseases.
27. Composition pour son utilisation selon l'une des revendications 18 ou 19, dans la prévention de l'athérosclérose.  27. Composition for its use according to one of claims 18 or 19, in the prevention of atherosclerosis.
28. Composition pour son utilisation selon l'une des revendications 18 ou 19, dans la prévention et/ou le traitement de maladies cardiovasculaires et/ou de l'hyperglycémie et de l'insulino résistance et/ou de l'hyperlipidémie.  28. Composition for its use according to one of claims 18 or 19, in the prevention and / or treatment of cardiovascular diseases and / or hyperglycemia and insulin resistance and / or hyperlipidemia.
29. Composition pour son utilisation selon l'une des revendications 18 ou 19, dans la prévention et/ou le traitement de l'hypertension, de l'artérite des membres inférieurs, de maladies coronariennes, de séquelles d'infarctus ou d'ictus cérébral. 29. Composition for its use according to one of claims 18 or 19, in the prevention and / or treatment of hypertension, arteritis of the lower limbs, coronary heart disease, after-effects of stroke or stroke. cerebral.
30. Composition pour son utilisation selon l'une des revendications 18 à 28 , en complément d'une restriction calorique, et/ou de la gestion chronique du stress et/ou de la pratique d'une activité physique. 30. Composition for use according to one of claims 18 to 28, in addition to a caloric restriction, and / or chronic management of stress and / or the practice of physical activity.
31. Utilisation d'une composition selon l'une des revendications 1 à 17, comme produit de nutrition à administration orale pour la prévention du risque cardiométabolique.  31. Use of a composition according to one of claims 1 to 17 as an oral nutrition product for the prevention of cardiometabolic risk.
32. Utilisation d'une composition selon l'une des revendications 1 à 17, comme produit de nutrition à administration orale pour diminuer la graisse viscérale et le gras sous- cutané profond chez les personnes en surcharge pondérale et/ou pour diminuer le tour de taille et/ou réduire le stress et/ou normaliser la tension artérielle et/ou diminuer l'inflammation CRP ultrasensible et/ou limiter la coagulation et/ou réguler le cholestérol et les triglycérides et/ou diminuer la glycémie et la glycémie post prandiale et/ou l'insulinémie et/ou diminuer l'hypersensibilité de la barrière intestinale et/ou rééquilibrer la flore intestinale et/ou remodeler la matrice cellulaire.  32. Use of a composition according to one of claims 1 to 17, as an oral nutrition product to reduce visceral fat and deep subcutaneous fat in overweight people and / or to reduce the risk of reduce and / or reduce stress and / or normalize blood pressure and / or decrease CRP inflammation and / or limit coagulation and / or regulate cholesterol and triglycerides and / or lower blood sugar and postprandial blood glucose and and / or insulinemia and / or decrease the hypersensitivity of the intestinal barrier and / or rebalance the intestinal flora and / or remodel the cell matrix.
33. Utilisation selon l'une des revendications 31 ou 32, en complément d'une restriction calorique, et/ou de la gestion chronique du stress et/ou de la pratique d'une activité physique.  33. Use according to one of claims 31 or 32, in addition to a caloric restriction, and / or chronic management of stress and / or the practice of physical activity.
EP14744782.5A 2013-07-02 2014-07-02 Composition involved in regulating energy cycle, inflammation and insulin resistance dysfunctions, and use thereof particularly in cardiometabolic diseases Withdrawn EP3046552A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR1356450A FR3007987A1 (en) 2013-07-02 2013-07-02 MEDICAMENT FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS AND METABOLIC OVERVOLTAGE
FR1356448A FR3007986A1 (en) 2013-07-02 2013-07-02 MEDICAMENT FOR CONTROLLING INFERTILITY AND SUB-FERTILITY IN PARTICULAR WITHIN METABOLIC FERTILITY OR INFERTILITY
FR1356444A FR3007984A1 (en) 2013-07-02 2013-07-02 MEDICAL NUTRITION PRODUCT FOR THE PREVENTION OF CARDIOMETABOLIC RISK AND HEPATIC STEATOSIS AND THE TREATMENT OF PRE DIABETES
FR1356446A FR3007985A1 (en) 2013-07-02 2013-07-02 MEDICAMENT FOR THE PREVENTION AND TREATMENT OF CARDIOMETABOLIC RISK FACTORS, IN PARTICULAR CARDIOVASCULAR DISEASES, PRE DIABETES, TYPE II DIABETES AND HEPATIC STEATOSIS
PCT/EP2014/064110 WO2015000986A1 (en) 2013-07-02 2014-07-02 Composition involved in regulating energy cycle, inflammation and insulin resistance dysfunctions, and use thereof particularly in cardiometabolic diseases

Publications (1)

Publication Number Publication Date
EP3046552A1 true EP3046552A1 (en) 2016-07-27

Family

ID=51257464

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14744782.5A Withdrawn EP3046552A1 (en) 2013-07-02 2014-07-02 Composition involved in regulating energy cycle, inflammation and insulin resistance dysfunctions, and use thereof particularly in cardiometabolic diseases

Country Status (3)

Country Link
US (1) US20160375061A1 (en)
EP (1) EP3046552A1 (en)
WO (1) WO2015000986A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3032883B1 (en) * 2015-02-24 2017-03-17 International Nutrition Res Company COMPOSITION FOR THE PREVENTION AND TREATMENT OF METABOLIC STEATOSIS AND STEATOHEPATITIS
FR3079142B1 (en) * 2018-03-23 2020-11-27 Matieres Premieres Int VETERINARY COMPOSITION CONTAINING SUPEROXIDE DISMUTASE AND AT LEAST ONE PROTEIN HYDROLYSATE RICH IN BIOASSIMILABLE PEPTIDES
ES2749717A1 (en) * 2018-09-21 2020-03-23 Biopeptide S L Composition and its uses (Machine-translation by Google Translate, not legally binding)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03004818A (en) * 2000-11-29 2003-09-10 Smithkline Beecham Corp Composition containing statins and calcium for improved cardiovascular health.
US20120214771A1 (en) * 2001-07-27 2012-08-23 Fontini Sampalis Compositions for treatment of cardiometabolic disorders
EP1534314B1 (en) * 2002-09-04 2014-10-22 DSM IP Assets B.V. A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
EP1827477B1 (en) * 2004-12-22 2015-10-21 DSM IP Assets B.V. Blood pressure lowering oligopeptides in a single enzymatic step
US20110130637A1 (en) * 2008-03-20 2011-06-02 University Of Dundee Protein product for modifying cardiovascular health
US8486922B2 (en) * 2010-04-28 2013-07-16 Chien-Hung Chen Composition
US20120177631A1 (en) * 2011-01-10 2012-07-12 Morteza Naghavi Composition for Health Promoting Compounds
GB2510712A (en) * 2011-07-22 2014-08-13 Karel Paul Bouter Nutritional product comprising a biguanide
FR2981545B1 (en) * 2011-10-25 2014-07-11 Internat Nutrition Res Company DIETETIC PRODUCT FOR REDUCING VISCERAL GREASE IN BARIATRIC PREOPERATIVE
FR2981544B1 (en) * 2011-10-25 2014-01-31 Internat Nutrition Res Company DIETETIC PRODUCT FOR PREVENTING CARDIOMETABOLIC RISK

Also Published As

Publication number Publication date
WO2015000986A1 (en) 2015-01-08
US20160375061A1 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
EP2770852B1 (en) Dietetic product for reducing visceral fat in bariatric preoperative phase
EP2770853B1 (en) Dietetic product for use in the prevention of the risk of a cardiovascular metabolic disorder
WO2012052685A1 (en) Product for treating cellulite, skin ageing and for preventing inflammatory processes
WO2016151269A1 (en) Eye health composition
CA2521967C (en) Nutritional or therapeutic composition containing the compound oleuropeine or one of the derivatives thereof
FR3007985A1 (en) MEDICAMENT FOR THE PREVENTION AND TREATMENT OF CARDIOMETABOLIC RISK FACTORS, IN PARTICULAR CARDIOVASCULAR DISEASES, PRE DIABETES, TYPE II DIABETES AND HEPATIC STEATOSIS
EP3046552A1 (en) Composition involved in regulating energy cycle, inflammation and insulin resistance dysfunctions, and use thereof particularly in cardiometabolic diseases
Houston Treatment of hypertension with nutrition and nutraceutical supplements: Part 2
JP2006131512A (en) Composition for accelerating secretion of adiponectin and food and drink containing the composition
WO2016062830A1 (en) Composition comprising plant proteins and use for preventing metabolic and cardiovascular pathological conditions associated with cardiometabolic risk in particular with hyperglycaemia
JP2007269631A (en) Agent for suppressing accumulation of neutral fat
EP2719291B1 (en) Dietetic product for long-term administration to patients after bariatric surgery
FR3007986A1 (en) MEDICAMENT FOR CONTROLLING INFERTILITY AND SUB-FERTILITY IN PARTICULAR WITHIN METABOLIC FERTILITY OR INFERTILITY
JP2018530319A (en) Combined composition for blood glucose control, liver protection, and prevention and treatment of related medical conditions
EP4007499B1 (en) Protein hydrolysate obtained from blue fish
FR3007987A1 (en) MEDICAMENT FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS AND METABOLIC OVERVOLTAGE
US20200197471A1 (en) S. spinosum extract for treating fatty liver disease
EP2719292B1 (en) Medical nutrition product intended for being administered to obese persons recently operated in bariatric surgery
JP2006342161A (en) Inhibitor of induction type nitric oxide synthase and food and drink
FR3007984A1 (en) MEDICAL NUTRITION PRODUCT FOR THE PREVENTION OF CARDIOMETABOLIC RISK AND HEPATIC STEATOSIS AND THE TREATMENT OF PRE DIABETES
JP2003261445A (en) Agent for suppressing neutral fat level in blood
BE1009446A6 (en) Use of cotton flour in a bread or biscuit formulation to obtain an iodine salt and/or vitamin vector, as medication or nutritional supplement intended for various uses, particularly therapeutic
Jiao et al. A review on animal and plant proteins in regulating diabetic kidney disease: Mechanism of action and future perspectives
EP3934451A1 (en) Method for enriching food products with proteins and/or with food supplements
WO2012156970A1 (en) Salvia sclarea seed oil for use in the treatment of cardiovascular diseases or anxiety disorders

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151228

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20161122

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170404